

APPLICATION FOR UNITED STATES LETTERS PATENT

5

for

COMPOSITIONS AND METHODS OF NEMATODE CONTROL

(Filed under 35 U.S.C. § 119 with Right to Priority)

This application claims benefit of U.S. Patent Application Serial No. 60/205,829 filed on May 19, 2000, entitled "Control of Nematodes, Stimulation of Nematode Resistance, and Screening Methods for Identifying Anti-Nematode Factors", incorporated herein by reference in its entirety and U.S. Patent Application Serial No. 60/274,358 filed on March 08, 2001, entitled "Control of Nematodes", incorporated herein by reference in its entirety.

Be it known that we, David Greenstein, a citizen of The United States of America, residing at 104 Groome Drive, Nashville, TN 37205 and Michael A. Miller, a citizen of The United States of America, residing at 2511 Barton Ave., Nashville, TN 37212; have invented new and useful "Compositions and Methods of Nematode Control".

FIELD OF THE INVENTION

The present invention is related to compositions and methods of nematode control and, in particular, to compositions and methods for control of nematode fertility, for identifying anti-nematode agents, and potentiating host resistance.

BACKGROUND OF THE INVENTION

Parasitic nematodes infection of plants and animals are widespread with approximately 3 billion people being infected worldwide, 100 million lives lost, and an estimated \$80 billion worth of crops lost annually to these organisms. Human conditions include river fever and elephantiasis each of which cause terrible human suffering. Parasitic nematodes are also a major problem in livestock, horses, and pets. Free living nematodes also damage plants during feeding, compete for oxygen, and transmit disease. Certain anti-nematode agents are commercially available. Disadvantages to these agents, such as the carbamates, include their extreme toxicity to most animals and all humankind. Other agents, such as ivermectin and its derivatives have undesirable toxic effects and potentially severe side effects especially those related to behavior and mental health. In addition, ivermectin resistant strains of nematodes develop relatively quickly and are reported in crops, livestock, and humans.

It is clear from the widespread and sever nature of the nematode problem and the adverse or toxic nature of many nematode treating agents, that more effective compounds and methods for controlling nematodes and identifying anti-nematode agents are needed.

STATUS OF THE PRIOR ART

McCarter et al, (1999) discloses that in the absence of sperm, the production of oocytes remains arrested in nematodes.

Klass, M. R., *et al.* (1981) discloses that major sperm protein is a structural protein in sperm cells of nematodes.

It is disclosed that all cells of *Caenorhabditis elegans* are directly observable in the intact *Caenorhabditis elegans* animal as reviewed in Hubbard and Greenstein (2000).

Video microscopy is disclosed to be used for observing the late stages of oocyte development (Ward and Carrel, 1979; Albertson, 1984; Albertson and Thomson, 1993; McCarter *et al.*, 1997; Rose *et al.*, 1997; Hall *et al.*, 1999).

SUMMARY OF THE INVENTION

The present invention provides, in part, compositions and methods for controlling nematode populations, identifying anti-nematode agents, enhancing host resistance to nematode infection, and treating plants and animals for nematodes.

Although the present invention is not bound by mechanism or theory, it is related, in part, to the surprising discovery made by the inventors that the major sperm protein (MSP) of nematodes is a molecular signaling factor which stimulates maturation of the female reproductive system in nematodes. Biological activities of MSP in this regard include, but are not limited to: oocyte maturation, gonadal sheath cell contraction, and ovulation.

One advantage of the present invention is that inhibitors of the MSP signaling mechanism described herein are contemplated to be highly specific to inhibiting nematode proliferation and spread while being non-toxic to vertebrates because the MSP gene and polypeptide are highly conserved between groups and divisions within the Phylum Nematoda, including the genera and species. Vertebrates and other non-nematode organisms, on the other hand, are not known to have an MSP gene, or protein. Thus, inhibitors of MSP stimulated female sexual maturation (FSM) are expected to be specific to organisms of the Phylum Nematoda.

Another advantage of the present invention is that the high sequence conservation observed among MSP from various nematodes suggests that resistance to anti-nematode agents that target MSP is likely to be minimal as mutational changes in MSP in are likely to result in a reduction of reproductive capacity.

5 Still another advantage of the present invention is that, in general, MSP and FSM effective domains thereof, can be prepared in soluble form. Thus, MSP provides an easily handled target for methods of the present invention including in high-throughput assays for identification of MSP binding and FSM blocking agents.

10 One aspect of the present invention includes a method for identifying an anti-nematode agent by contacting a test compound to a nematode and monitoring the FSM response, wherein inhibiting test compounds are selected as anti-nematode agents.

15 Another aspect of the present invention includes identifying anti-nematode agents by selection of major sperm protein binding agents as many of these agents will also inhibit FSM. Screening methods are described to determine which MSP binding agents also inhibit FSM.

In a further aspect of the present invention, a reduction or an absence of MSP signal transduction impairs or virtually eliminates nematode fertility.

20 Still further aspects of the present invention provide methods of controlling nematode populations including, but not limited to: free living nematode populations and parasitic nematode populations which, in turn include animal and plant parasitic nematodes.

25 Additional aspects, embodiments, and elements of the present invention are described below, including in the detailed description of the invention, the examples, and the claims. Aspects, embodiments, and elements described herein are not meant to limit the present invention in any way including to any particular set

thereof. Further aspects, embodiments, elements and equivalents thereof, will be readily apparent based upon the present disclosure and are considered to be within the spirit and scope of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

- 5 FIG. 1 shows a cross-section of a nematode and includes a depiction of the reproductive anatomy. Microinjections as described herein are preferred to be carried out at the point indicated.
- 10 FIG. 2 shows a polyacrylamide gel electrophoresis of crude sperm-conditioned medium (SCM) (left lane) and isolated 14 kDa female sexual maturation (FSM) stimulating factor (single band in right lane) identified as major sperm protein (MSP) of *C. elegans*.
- 15 FIG. 3 shows HPLC traces of fractionation of SCM on C-4 and C-18 columns. The "+" sign indicates the respective fractions with FSM positive biological activity.
- 20 FIG. 4 shows mass spectra of the FSM positive fractions from the HPLC purification. The mass spectra confirm MSP-3 and MSP-142 of *C. elegans* are present in the biologically active SCM. No other factors were observed or identified in these mass spectra.
- 25 FIG. 5 is a diagram of MSP mediated cellular communication between female reproductive cell (for example, the oocytes) and sperm.
- FIG. 6 displays an alignment of twenty-seven MSP polypeptides from *C. elegans*. The SEQ ID Numbers are not meant to include the N-terminal most methionine which is believed to be cleaved during processing.
- FIG. 7 displays and alignment of *Ascaris suum* alpha and beta MSP isoforms and MSP-142 of *C. elegans*. Again, the SEQ ID Numbers are not meant

to include to N-terminal most methionine which is believed to be cleaved during processing.

FIG. 8 is a bar graph demonstrating bioactive properties of MSP-77 and MSP-38, and sperm protein (versus and buffer control) in stimulating FSM in nematodes. The top panel displays maturations per hour which is a biological measure of oocyte maturation. The center panel displays contractions per minute which is a biological measure of sheath cell contraction. The bottom panel displays average displacement (in microns) which is another measure of sheath cell contraction. Measurements are made for buffer and the shown concentrations of MSP-77, MSP-38, and sperm MSP. The 6His marking denotes that the MSP includes a histidine tag (Qiagen) and was purified using this system.

FIG. 9 shows an alignment (performed by visual inspection) of the C-termini of MSPs from wide ranging nematode species and demonstrates that there is a remarkable sequence conservation. The residues numbers relative to the full length (minus the methionine) polypeptide are 106-126 for each of the following. *Ascaris suum* (As) MSP isoforms alpha and beta (GenBank accession numbers P27439 and P27440) fragment from 106-126 are both represented by SEQ ID NO:13 (identical polypeptides). *Onchocerca volvulus* (Ov) MSP isoforms 1 and 2 (P13262 and P13263) are also represented by SEQ ID NO:13. *Globodera rostochiensis* (Gr, the potato cyst nematode) MSP isoforms 1, 2, and 3 are each represented by SEQ ID NO:14. *C. elegans* (Ce) MSP isoforms 142 and 33 (P53017 and P53019) are each represented by SEQ ID NO:15.

FIG. 10 is a bar graph showing that the N-terminal region of MSP is necessary and sufficient for stimulation of oocyte maturation and the C-terminal region is necessary and sufficient for stimulation of sheath cell contraction. The N-terminal residues 1-106 (SEQ ID NO: 16) of MSP-77 (SEQ ID NO:9) are necessary and sufficient for stimulation of oocyte maturation (top panel). The C-terminal residues 106-126 (SEQ ID NO:17) of MSP-77 (SEQ ID NO:9) are necessary and sufficient for stimulation of sheath cell contraction (middle panel) and displacement (bottom panel).

DETAILED DESCRIPTION OF THE INVENTION

Given the human suffering and economic loss due to nematodes, it is critical that effective and safe anti-nematode compounds and methods for controlling nematodes are identified. Although not bound by mechanism or theory, the present invention takes advantage of the discovery by the inventors that nematode major sperm protein regulates the fertility of nematodes. Provided herein are compositions and methods for inhibiting or blocking major sperm protein action in fertility.

Certain utilities of the compositions and methods of the present invention include, but are not limited to: identifying anti-nematode agents, manufacturing anti-nematode agents, providing reagents for screening test compounds for anti-nematode activity, controlling nematode populations, treating animals and plants for nematode infection or infestation, treating animals and plants for certain negative effects of nematodes (including environmental or other effects of free living nematodes), raising host resistance to nematode infection, and prophylactic treatments to retard nematode infection or the spread of nematodes.

1.0 Definitions

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In case of conflict, the present document, including
5 definitions, will control.

Descriptions of preferred methods and compositions are provided herein, but should not be construed to be limiting.

As used herein "prophylaxis" or "prophylactic treatment" refers to measures designed to preserve health or retard the spread of disease. "Prophylaxis" or
10 "prophylactic treatment" do not mean herein a certainty of the preservation of health or a certainty of a halt to a spread of a disease.

MSP is an abbreviation for major sperm protein.

FSM is an abbreviation for female sexual maturation.

FSM is meant to include, but is not necessarily limited to oocyte maturation,
15 sheath cell contraction, and ovulation.

SCM is an abbreviation for sperm-conditioned media.

C. elegans is an abbreviation for the nematode genus and species
Caenorhabditis elegans.

A. suum is an abbreviation for the nematode genus and species *Ascaris suum*.

20 The term "biological activity" is meant to include, but is not limited to: FSM, oocyte maturation, sheath cell contraction, and ovulation.

The term "polypeptide" is known in the art, meanings of which are included herein. However, in the event of conflict, the term "polypeptide" means herein, an amino acid polymer of two units or greater (e.g., a dipeptide or greater).

The term “polynucleotide” is known in the art, meanings of which are included herein. However, in the event of conflict, the term “polynucleotide” means a nucleic acid polymer of two units or greater (*e.g.*, a dinucleotide or greater).

5 The term “isolated polypeptide” refers to a polypeptide that is at least partially removed from the milieu of molecules in which it occurs in nature.

10 The term “isolated polynucleotide” refers to a polynucleotide that is at least partially removed from the milieu of molecules in which it occurs in nature. As used herein, “isolated polynucleotide” also means that the polynucleotide is not identical in structure to a naturally occurring genome or fragment of a genome that spans more than three distinct, non-overlapping, genomically consecutive genes in length.

Additional definitions of specific terms and phrases are provided herein as needed.

2.0 *Caenorhabditis Elegans* as a Model System

15 *Caenorhabditis elegans*, or *C. elegans*, is a widely accepted genetic model system for studying the genes and gene functions of higher organisms. *C. elegans* is also a widely accepted model system for studying all features of other members of the phylum Nematoda. These features include germline development, female sexual maturation, oocyte maturation, sheath cell contraction, and ovulation (reviewed by Hubbard and Greenstein, 2000).

20 *C. elegans* is a primitive organism which nonetheless shares many of the essential biological characteristics that are central problems of, for example, human biology. The worm is conceived as a single cell which undergoes a complex process of development, starting with embryonic cleavage, proceeding through morphogenesis and growth to the adult. It has a nervous system including a rudimentary brain,
25 exhibits behaviors, and can “learn”. It produces sperm and eggs, mates and

reproduces. After reproduction it gradually ages, loses vigor and finally dies. Certain genetic features of *C. elegans* have been extensively characterized and the genome has been sequenced. All 959 somatic cells of its transparent body are visible with a microscope, and its average life span (in the normal state) is a mere 2-3
5 weeks. Thus, *C. elegans* provides an ideal compromise between complexity and tractability.

3.0 Germline Development in Nematoda

In general, sexual reproduction of nematodes depends on coordination between meiotic cell cycle progression, gametogenesis, and fertilization. For
10 example, gamete differentiation is coordinated with meiotic cell cycle transitions so that fertilization produces a diploid zygote capable of completing embryogenesis and growing into a fertile adult. Normally, nematode oocytes arrest during diplotene/diakinesis of meiotic prophase (after the completion of meiosis I and meiosis II) while they grow in size. The release of oocytes from this arrest occurs
15 during meiotic maturation during which the nuclear envelope (*i.e.*, germinal vesicle) breaks down, the cytoskeleton rearranges, and the oocyte prepares for fertilization.

Typically, the progression of germline development in *C. elegans*, and members of Nematoda in general, is as follows. During embryogenesis a reproducible and largely invariant cell lineage generates two germline precursor
20 cells, Z2/Z3, and two somatic gonadal precursor cells, Z1/Z4, that together comprise the gonadal primordium at hatching (Kimble and Hirsh, 1979; Sulston *et al.*, 1983). During post-embryonic development, Z1 and Z4 give rise to the entire somatic gonad (in the hermaphrodite, these structures are distal tip cells (DTCs), sheath cells, spermathecae, and uterus) and Z2 and Z3 give rise to the germ line. In later
25 larval stages the germ line contains a stem-cell population that contributes cells to

the meiotic pathway. Although germline nuclei reside in a syncytium at these stages, individual germline nuclei and their surrounding cytoplasm are typically referred to as a "germ cell". Development of the soma and germ line in both sexes, hermaphrodites and males, is coordinated by intercellular signaling. The self-fertile hermaphrodites are essentially modified females that produce sperm for a short time early in gametogenesis and then produce exclusively oocytes as adults. Males produce only sperm and can mate with hermaphrodites to produce cross progeny.

During post-embryonic development germ cells proliferate mitotically forming approximately 1000 nuclei in hermaphrodites and 500 in males. The *C. elegans* adult hermaphrodite gonad consists of two U-shaped gonad arms (FIG. 1). The two equivalent gonad arms of the adult hermaphrodite gonad have been described at an ultrastructural level (Hirsh *et al.*, 1976; Hall *et al.*, 1999; see FIG. 1). The distal portion of the gonad contains syncytial germline nuclei surrounded by incomplete membranes. The germ cells are connected to a core cytoplasm, also called the rachis. The stem-cell population is restricted to the distal-most part of the germ line; germ cells enter meiosis as they move proximally. In hermaphrodites, approximately the first 40 germ cells to enter meiotic prophase in each gonad arm differentiate as spermatocytes which complete meiosis to form approximately 160 sperm during the fourth larval stage of development. Upon progression to the adult stage, the germ cells differentiate as oocytes. Oocytes are surrounded by the proximal gonadal sheath cells (see FIG. 1).

The gonadal sheath cells are somatic cells that appear to play several roles important for the structure, integrity, and reproductive functions of the gonad (McCarter *et al.*, 1997; Rose *et al.*, 1997). The ten thin gonadal sheath cells can be subdivided into five pairs (1-5) with each pair having a distinct position along the proximal-distal axis of each gonad arm (FIG. 1). These elongated myoepithelial cells

lie between germ cells and the gonadal basal lamina (Hirsh *et al.*, 1976; Kimble and Hirsh, 1979; Strome, 1986; Hall *et al.*, 1999). The distal sheath cells (pair 1) have an unusual cellular structure with a flattened soma pressed into the gonad such that the cytoplasm is concentrated into a series of wedges that insert between the germ cells. Pair 1 distal sheath cells also extend finger-like filopodia between distal germ cells. Pair 2 ensheathes the loop region. The proximal sheath cells (pairs 3-5; see FIG. 1) contain thick and thin filaments and contract to drive ovulation (Strome, 1986; Myers *et al.*, 1996; McCarter *et al.*, 1997; Rose *et al.*, 1997; Hall *et al.*, 1999). The proximal sheath cells are positioned in an interdigitating pattern form gap junctions with one another, and are closely apposed to oocytes (Hall *et al.*, 1999). On their basal surfaces the proximal sheath cells attach to the gonadal basal lamina via hemi-adherens junctions which also serve to anchor the actin cytoskeleton and the contractile apparatus within the sheath cells. At their apical face, the proximal sheath cells often form gap junctions with oocytes. Yolk particles synthesized by the intestine (Kimble and Sharrock, 1983) gain access to oocytes for receptor-mediated endocytosis (Grant and Hirsh, 1999) by first moving through the sheath pores (Hall *et al.*, 1999). The most proximal sheath cells, pair 5, directly attach to the spermatheca. The spermatheca (1 per gonad arm) is a flexible accordion-like structure connected to the gonad arm distally and to the uterus proximally. The spermatheca expands greatly to accommodate oocytes, which are fertilized as they enter from the gonad arm during ovulation.

4.0 Female Sexual Maturation

The phrase "female sexual maturation" is defined herein to include, but is not limited to: meiotic maturation, completion of the meiotic divisions, oocyte production, oocyte or ovum maturation, and the events and processes of sheath cell

contraction and ovulation. In certain embodiments, "maturation" generally relates to the process by which an oocyte or an ova becomes competent for being fertilized. For example, female sexual maturation includes maturation of a female reproductive cell and maturation of an oocyte. In another example, as used herein, 5 female sexual maturation also includes a contraction of a sheath cell which is considered herein to be a female reproductive cell. Thus certain cells of the nematode reproductive system are referred to as female reproductive cells, even though they are not an oocyte or ovum per say.

5.0 Meiotic Maturation, Ovulation, and Completion of the Meiotic Divisions

10 Fully grown oocytes remain in the diakinesis stage of prophase I prior to undergoing meiotic maturation, ovulation, and fertilization. The nuclear envelope of the most proximal oocyte breaks down about 5 minutes prior to ovulation as it enters meiotic M-phase from prophase (Ward and Carrel, 1979; McCarter *et al.*, 1999). During maturation, the oocyte also undergoes a structural change termed 15 cortical rearrangement (McCarter *et al.*, 1999). These changes within the oocyte coincide with a reproducible sequence of somatic motor events mediated by the proximal sheath cells and the distal spermatheca resulting in ovulation. During ovulation the mature oocyte enters the spermatheca and is fertilized. The fertilized oocyte then passes into the uterus where both meiotic divisions are completed and 20 embryogenesis begins (Albertson, 1984; Albertson and Thomson, 1993; McCarter *et al.*, 1999). McCarter *et al.*, (1999) discloses that in the absence of sperm, the production of oocytes remains arrested in nematodes.

6.0 Assay to Identify the Stimulator of Female Sexual Maturation

The present inventors developed an *in vivo* assay for female sexual 25 maturation and used the assay to discover that the major sperm protein (MSP) is

the particular stimulator of female sexual maturation. The general procedures used are as follows. Large quantities of sperm (>108) are purified using a modification of methods developed by Klass and Hirsh (1981). Synchronized cultures of *fog-2(q71)*, which are 50% male and 50% female, are used to purify adult males (Lewis and
5 Flemming, 1995). Mutations in the *fog-2* gene block spermatogenesis in *XX* animals, transforming them into females, but have no effect on *X0* animals, which are fertile males (Schedl and Kimble, 1988). Males are separated from females, larvae, and embryos based on size by sieving through NITEX screens of various pore sizes. The populations of males isolated in this way are generally >99% pure. To isolate sperm,
10 males are placed between two PLEXIGLASS plates and smashed in a vice grip (The Home Depot, Inc.). Intact sperm are then purified from the carcasses by filtration through NITEX filters (20 micron pore size) and washed in M9 phosphate buffer (Sulston and Hodgkin, 1988) using several rounds of low speed centrifugation and resuspension. Sperm-conditioned medium (SCM) are prepared by incubating
15 purified sperm in M9 for different periods of time (*e.g.*, 1-12 hours) and removing the sperm by centrifugation and filtration through a 0.2 micron filter. Microscopic analysis suggests that the sperm are not lysing during the incubation. Polyacrylamide gel electrophoresis (PAGE) also indicates that the sperm are not lysing during the incubation and also reveals that that an approximately 14 kDa
20 protein is enriched in SCM. Referring to FIG. 2, a single protein band at approximately 14 kDa is apparent in the second lane. PAGE results for unfractionated SCM are displayed in lane 1.

Another aspect of the present invention provides an assay to screen SCM for maturation- and contraction-inducing activities, comprising microinjecting SCM
25 into the uterus of reduced capacity sperm producing female nematodes (virgin *fog-2(q71)* females are used in certain preferred embodiments). Maturation and sheath

cell contraction are monitored by time-lapse video microscopy (see Rose *et al.* (1997) for a general description of time-lapse video microscopy of nematodes). Dramatic increases in oocyte maturation and sheath cell contraction rates are observed following injection of SCM. By contrast, no activity, or essentially no activity, is observed following injection of female extracts, 1-methyladenine, acetylcholine, oxytocin, or M9 buffer. The above described embodiment, provides a bioassay for sperm derived factors that promote oocyte maturation and sheath cell contraction. It is disclosed in the present invention that the activity is, at least in part, soluble and present in the sperm-conditioned media. This suggests that the factor is secreted by the sperm. Thus, it is a discovery of the present invention that while the sperm are sometime physically blocked by the valve, a soluble (diffusible) factor is secreted from the sperm to affect FSM and this factor penetrates the valve.

Still another aspect of the present invention provides compositions and methods for fractionation of SCM, and other nematode biological materials, for isolation of the FSM stimulatory factor. In one example, fractionation is performed using reversed phase high pressure liquid chromatography (HPLC) on Vydak C-4 and C-18 analytical columns. FIG. 3, a fraction marked by a + sign is the only active fraction recovered when the SCM is fractionated on the C-4 and C-18 columns, respectively (as determined using the *in vivo* FSM assay described herein). The biologically active fraction is analyzed using MALDI mass spectrometry peptide mapping and sequencing, identification techniques which are known in the art (FIG. 4). This result is verified by producing MSP-38 (GenBank Ac. # CAA93089) and MSP-142 (GenBank Ac. # CAB03037) in bacteria and purifying the respective isoforms using a commercially available 6-His tagging and protein product purification system. The inserts are cloned into the pQE-30 Type IV Kit available from Qiagen. The vector includes the 6-His tagging system and methods for this

cloning and use of the 6-His tagging system of identification and purification of expressed polypeptides are well known. The result is also confirmed using *C. elegans* MSP-77. Additional tests by MADLI-MS analysis demonstrate the *C. elegans* MSP in SCM is MSP-3 and MSP 142 (Miller *et al.*, 2001).

5 Microinjection of purified recombinant MSP mimics the biological response (FSM) seen using the active, fraction purified from SCM. Additionally, the recombinantly produced protein yields the same peptide map as the MSP from the active SCM fraction when cleaved with trypsin and analyzed using mass spectrometry. These results demonstrate that *C. elegans* sperm secrete, or
10 otherwise release, the major sperm protein, that the MSP signal is at least partially soluble in the extracellular fluid surrounds the sperm and in buffers, and that MSP dramatically increases FSM (including oocyte maturation, sheath cell contraction, and ovulation rates). The concept of MSP directed signal transduction of FSM including oocyte maturation, sheath cell contraction, and ovulation is diagrammed
15 in FIG. 5. Referring to FIG. 5, MSP serves as a simple molecule for communication between the sperm and non-mature or arrested oocytes and inactive female reproductive cells that sperm is present and ready to fertilize the egg.

 Furthermore, the MSP is believed to be necessary and sufficient for stimulating that communication or signal transduction of FSM. While it is
20 contemplated and other factors may form a web-like network of upstream and/or downstream signal cascade, it is an advantage in certain embodiments herein that the role of MSP is quite uncomplicated. Thus, MSP provides an excellent target for anti-nematode agents. Also, due to the high sequence conservation between MSP polypeptides in all known nematodes, it is contemplated that nematodes will not
25 readily evolve resistance to compounds or agents that target MSP.

7.0 MSP is Known as a Structural Protein Localized Within the Sperm Cell

MSP is known in the art as a structural protein of the nematode sperm (Klass, M. R., *et al.*, 1981). Thus, it is a surprising discovery of the present invention that MSP is also a nematode female sexual maturation factor (stimulator, signal transduction element, etc.).

It is widely accepted that motility of nematode sperm is not actin based, but rather is dependent upon MSP structure and function. Inside the sperm cell, dimeric MSP assembles at one end of a fibrous polymer of dimeric MSP and disassembles at the other end in a treadmill-like fashion which enables the sperm to protrude and withdraw pseudopodia related to motility.

8.0 Sequence Conservation Among the Many MSP Sequences Described

There are likely more than sixty copies of the MSP gene in the *C. elegans* genome and it is believed that most of these MSP genes are transcribed. Referring to FIG. 6, twenty-seven MSP polypeptide sequences are provided corresponding to polypeptides transcribed from apparently distinct MSP genes or polynucleotide sequences. Certain other nematodes apparently have fewer copies of MSP. For example, *A. suum* are believed to have two copies of an MSP gene both of which are believed to be transcribed into polypeptides.

Twenty-seven polypeptide sequences for FIG. 6 are aligned using Divide-and-Conquer Multiple Sequence Alignment which is currently available over the world wide web (www) at the URL <http://bibiserv.techfak.uni-bielefeld.de/dca/>. The server is located at the Practical Computer Science and Bioinformatics research group which is run by Robert Giegerich. The physical location is: Robert Giegerich, AG Praktische Informatik, Technische Fakultät, Universität Bielefeld, Postfach 10 01 31, D-33501 Bielefeld, Germany. The parameters used are Blossum 62 predefined

substitution matrix, free shift activated, approximate cut positions activated, recursion stop size L set to 20, window size W set to 0, and weight intensity lambda set to 0. The algorithm and method are disclosed in Stoye (1998).

Referring to FIG. 6, it is known that the N-terminal most methionine (from the ATG translation start site) is cleaved. It is expected that both forms (with and without the methionine) of MSP polypeptides are active in FSM; therefore, the methionine was included in FIG. 6. However, the references to the SEQ ID Numbers provided in FIG. 6 correspond to MSP polypeptide sequences of 126 amino acids and are without each N-terminal most methionine as shown in FIG. 6.

Again, referring to FIG. 6, the sequences of the numerous *C. elegans* MSP display a high degree of sequence homology. Very few sequence variations are observed. Residues that vary from the global (general) consensus within a column (determined visually) are marked in bold letter and underlined in FIG. 6. Because MSP polypeptide sequences, and even those of the most divergent known nematodes (see below), are so highly conserved; the preferred method for alignment is by visual inspection. For example, two or more MSP polypeptide sequences can be easily lined up next to one another on a computer screen or as written out on a paper and one moved against another until the majority of the bases match. Percent identity between any two sequences is calculated by counting the number of residues that do not match, dividing by the total number of residues in the total sequence being compared (or the shortest of the sequences being compared if one of the pair is shorter in length), multiplying by 100, and expressing the resulting value as a percent.

Using this approach, one of ordinary skill in the art can easily determine an alignment of a given MSP isolated from any member of the phylum Nematoda to another MSP, including to a *C. elegans* MSP, and in preferred embodiments the

MSP specified in SEQ ID NO:2. It is also preferred that the alignment selected is the one which produces the highest sequence identity as described above.

Thus, for example, the visual inspection method described above is used to align the sequences for the two known MSPs from *A. suum* (alpha and beta) with
5 MSP-142 of *C. elegans* (see FIG. 7). Again, very little sequence variation is observed between MSP polypeptides from these nematodes that are separated by hundreds of millions of years of evolutionary pressure. This indicates that the structure function relationship in MSP is tight and sequence variation likely results in a reduced fitness of the organism.

10 9.0 Biological Activities of MSP on FSM are Conserved in Phylum Nematoda

Ascaris suum is believed to be one of the most widely separated nematode species from *C. elegans* in terms of both evolution (hundreds of millions of years post divergence from the common organism) and in terms of distinctness of the MSP sequence including at the polypeptide level. For example, evaluation of the
15 biological activity of isolated MSP alpha and MSP beta from *A. suum* in the *in vivo* FSM assay described above serves as a model system for demonstrating that MSP sequences in general stimulate nematode FSM in all or nearly all member of the phylum Nematoda.

MSP, isoforms alpha from *A. suum* is isolated from *A. suum* nematodes or the
20 corresponding nucleotide is cloned and expressed in bacteria, for example. The specific sequence used is Accession Number P27439 in the NCBI database (maqsvppgdintqpsqkivfnapyddkhtyhikitnaggrrigwaikttnmrrlsvdppcgvl dpkekvlmav scdtfnaatedlnndritiewtntpdgaakqfrrewfqgdgmvrknlpieynl) and is set forth in SEQ ID NO: 11, wherein SEQ ID NO:11 does not include the N-terminal methionine in

order to represent the polypeptide that is believed to be cleaved during cellular processing (see FIG. 7).

MSP, isoforms beta from *A. suum* is isolated from *A. suum* nematodes or the corresponding nucleotide is cloned and expressed in bacteria, for example. The specific sequence used is Accession Number P27440 (maqsvppgdintqpgskivfnapyddkhtyhikitnaggrrigwaikttnmrrlgvdppcgvl dpkesvlmavscdtfnaatedlnndritiewtnptdgaakqfrrewfqgdgmvrnknlpieynl) in the NCBI database and is set forth in SEQ ID NO: 12, wherein SEQ ID NO:12 does not include the N-terminal methionine in order to represent the polypeptide that is believed to be cleaved during cellular processing.

Microinjection of MSP, isoform alpha or MSP, isoform beta into the sperm defective (or reduced sperm capacity) female *C. elegans* as described above results in a restoration of apparently normal FSM biological activity even though no sperm are added. This provides support for using any combination of MSP polypeptide including as expressed from MSP polynucleotides. Methods known in the art for expressing polynucleotides that are preferred herein include, but are not limited to: expression in bacteria, transient expression in nematodes, stable expression in nematodes, and transgenic expression in nematodes. Transgenic expression in nematodes includes gonadal specific expression and ectopic expression, such as in transgenic expression in somatic cells of the nematode.

10.0 Experiments Demonstrating that MSP Stimulates FSM

The biological activities of MSP-77 and MSP 38 are studied using the *in vivo* FSM assays described herein. Referring to FIG. 8, MSP isolated from male nematodes, as well as MSP produced in bacteria stimulate oocyte maturation and sheath cell contraction when introduced into female nematodes with reduced sperm

formation such as *fog-2* mutants (MSP-77 and MSP-38, in this figure, are isolated from the bacteria with a 6His tag. This general protein isolation technique is known in the art). Again, referring to FIG. 8, the top panel displays maturations per hour which is a biological measure of oocyte maturation. The center panel displays
5 contractions per minute which is a biological measure of sheath cell contraction. The bottom panel displays average displacement (in microns) which is another measure of sheath cell contraction. Measurements are made for buffer and the shown concentrations of MSP-77, MSP-38, and sperm MSP. The 6His marking denotes that the MSP includes a histidine tag (Qiagen) and was purified using this
10 system.

Similar experiments are performed with MSP-3 and MSP-142 (which are identified herein to be localized in sperm-conditioned medium), and MSP from *C. briggsae* and *C. remanei*. Also, experiments are performed with MSP from the distantly related *A. suum*. Each experiment demonstrates that MSP is essentially
15 interchangeable with regard to its biological activities in FSM.

11.0 The Carboxyl-Terminus of MSP Shows High Sequence Conservation

Residues 105 through 125 of MSPs derived from nine different genera of nematodes show a 100% sequence identity in these 19 consecutive amino acid residues (see FIG. 9). These nematodes represent free-living (*C. elegans*), animal
20 parasites (*Ascaris* and *Onchocerca*), and plant parasites (*Globodera*). (Specifying these genera as free-living, animal parasites, or plant parasites is not meant to limit the range that Nematodes inhabit the environment. In general many groups of nematodes have a diverse range)

12.0 Certain Domains Within MSP Differentially Stimulate FSM Activities

Another aspect of the present invention provides that certain domains within MSP differentially regulate certain FSM activities. For example, FIG. 10 demonstrates that residues 1-106 (SEQ ID NO:16) of MSP-77 (SEQ ID NO:9) preferentially stimulates oocyte maturation, while residues 106-126 (SEQ ID NO:17) of MSP-77 (SEQ ID NO:9) preferentially stimulates the rate of sheath cell contraction and displacement.

Thus, the biological activities of FSM, including oocyte maturation and sheath cell contraction, can be separated and the present invention discloses that different domains within MSP are capable of regulating those activities independently.

13.0 Description of MSP Sequence Fragments

Still another aspect of the present invention includes compositions and methods for identifying and using domains within MSP including for differential regulation of the biological activities of FSM. For example, specific sized segments of MSP polypeptide are systematically screened for the impact of that domain on FSM. This provides a fine resolution map of the MSP polypeptide with regard to FSM function that can be exploited to identify and manufacture highly specific anti-nematode agents, for example. This is also useful, for example, to identify FSM related domains of particularly high sequence conservation among members of Nematoda and/or to avoid areas that might include a short region that is similar to a gene or polypeptide in another organism, the targeting of which with anti-organism agents is not desired.

In certain embodiments antibodies (polyclonal and/or monoclonal) are generated against each fragment for use in labeling, identification, and an assay of

the present invention. In preferred embodiments, the antibodies are raised against those segments of MSP that influence FSM (either positively or negatively). In other embodiments, the antibodies are raised by injection of the MSP, or the FSM active domain of the MSP, into an animal (in certain embodiments, a non-human animal) using techniques known to one of skill in the art for producing antibodies. In other embodiments, the antibodies and preferably monoclonal antibodies are produced in cell, such as hybridomas or by recombinant techniques that are known in the art. In certain embodiments, the antibodies are produced in humanized form. This can be accomplished in certain embodiments by injection of the immunogenic fragment of MSP into a human.

14.0 Production of MSP Polypeptide Fragments

Segments of MSP polypeptide sequences are readily manufactured by chemical synthesis, for example by solid phase polypeptide manufacture. Alternatively, such segments can be cloned, synthesized in a heterologous cell system, and isolated. Chemical synthesis is preferred for embodiments wherein the polypeptide is a polymer of 50 residues or fewer. Segments are polypeptides that are generally 10 amino acids or more in length (referring to consecutive amino acids in an MSP sequence in this section entitled Production of MSP Polypeptide Fragments). Although, in certain embodiments useful segments are contemplated that include fewer than 10 consecutive MSP amino acids. It is believed herein that all or nearly all MSPs are essentially interchangeable with each other in regard to FSM activity. Although differences may be identified when examining the differential regulation of FSM activity.

Segments do not include the full length MSP polypeptide sequence. For example, the 126 consecutive amino acids of SEQ ID NO:2 is not a segment.

Segments of a 126 amino acid MSP include 125 or fewer of consecutive amino acids of the MSP. It is preferred that the segment includes 120 or fewer, 110 or fewer, 106 or fewer, 105 or fewer, 100 or fewer, 95 or fewer, 90 or fewer, 85 or fewer, 80 or fewer, 75 or fewer, 70 or fewer, 65 or fewer, 60 or fewer, 55 or fewer, 50 or fewer, 45 or fewer, 40 or fewer, 30 or fewer, 25 or fewer, 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, or 10 or fewer consecutive amino acids of an MSP. An MSP alignment variant means that amino acids may be substituted in any given MSP or MSP segment to make that position identical to the same position in another MSP molecule including from diverse groups of Nematoda. The segments may also be MSP alignment variant which may be referred to herein as MSP alignment variant segments. Functionally equivalent sequences and biological functional equivalents are also generally considered to be within the spirit and scope of the present invention and are described below.

Ranges of segments are also provided in certain embodiments of the present invention. For example, a 10 amino acid segment may be selected from any portion of the MSP polypeptide. An 11 amino acid segment may be selected from any portion of the MSP polypeptide. Segments of lengths including 9 amino acids (consecutive in an MSP), 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 106, 110, 115, 116, 117, 118, 119, 120, 121, 122, 123, and 124 are contemplated for certain embodiments.

These segments are generally screened for FSM activity or used in assays to identify MSP binding agents (e.g., agents that bind to specific domains) and to identify anti-nematode agents. Although many segments are described, they can be screened readily for FSM activity given the present disclosure and without undue

burden. A preferred method of screening is to utility high-throughput assays such as in microtitre plates or other multiple-sample format to rapidly examine a large number of segments. Such general assay are known in the art and are provided herein with regard to MSP and the embodiments of the present invention.

5 15.0 Description of Certain MSP Sequences

Numerous examples of MSP sequences (including polynucleotide and polypeptide) are known in the art and are useful for various embodiments of the present invention. Also, additional MSP sequences including from additional nematodes types and species can be readily determined, without burden, using conventional cloning techniques and the fact that many sequences are described. Thus, for example, primers can be designed to pull out additional polynucleotides from a pool, such as a gene or genomic library, including by PCR amplification. These polynucleotide can be expressed using standard cloning techniques and the MSP activity of the resulting polypeptide is measurable based upon the assays disclosed herein. Certain known and described MSPs are provided by way of example in Table 1 below. The MSPs are represented by Accession Numbers corresponding to files in the publicly available database maintained by the National Center for Biotechnology Information (the NCBI database). These files include polynucleotide sequences and polypeptide sequences of MSP. All information within each file identified by Accession Number is hereby incorporated herein by reference.

The NCBI database is available on the world wide web at URL "http://www.ncbi.nlm.nih.gov/" and is physically located at: National Center for Biotechnology Information; National Library of Medicine; Building 38A, Room 8N805; Bethesda, MD 20894

TABLE 1

Nematode Identifier	Nucleotide Accession Numbers	Protein Accession Numbers
<i>Mansonella ozzardi</i>	AJ404225	CAC20724
	AJ404224	CAC20723
	AJ404223	CAC20722
	AJ404222	CAC20721
	AJ404221	CAC20720
	AJ404220	CAC20719
	AJ404219	CAC20718
	AJ404218	CAC20717
	AJ404217	CAC20716
	AJ404216	CAC20715
	AJ404215	CAC20714
	AJ404214	CAC20713
	AJ404213	CAC20712
	AJ404212	CAC20711
	AJ404211	CAC20710
	AJ404210	CAC20709
	AJ404209	CAC20708
		CAC20742
<i>Onchocerca volvulus</i>	AJ404208	CAC20741
	AJ404207	CAC20740
	AJ404206	CAC20739
	AJ404205	CAC20738

Inventors: Greenstein and Miller
 Attorney Docket: N-7088-MJM
 Customer No. 23456

	AJ404204 J04663 J04662	B45528 A45528
<i>Ascaris suum</i>	X94249	A45944 P27439 P27440 AAB23264 CAA63933
<i>Ascaris lumbricoides</i>	M15680	AAA29375
<i>Globodera rostochiensis</i>	L24501 L24500 L24499	AAA29148 AAA29147 AAA29146
<i>Pratylenchus penetrans</i>		AAB02264 AAB02263 AAB02262 AAB02251 AAB02250 AAB02249
<i>Pratylenchus scribneri</i>		AAB02242 AAB02241 AAB02240 AAB02239

16.0 An Assay for Female Sexual Maturation

A method is provided of identifying an anti-nematode agent, by contacting a test compound to a nematode and monitoring a female sexual maturation of the nematode, wherein inhibition of the female sexual maturation indicates that the test compound includes the anti-nematode agent.

The *in vivo* bioassay is useful, for example, to identify sperm-related factors that promote oocyte maturation and gonadal sheath cell contraction. The assay is also useful, as another example, for identifying agents that inhibit nematode female sexual maturation.

In certain embodiments of the assay, mutant nematodes are utilized which have a reduced capacity for sperm production, or lack the capacity altogether. Such mutants are disclosed to have either low rates of oocyte maturation and sheath cell contraction activity or none at all. The present invention provides compositions and methods for using these mutants to screen for factors that stimulate or inhibit female sexual maturation. In similar embodiments, compositions and methods are provided that for using transgenic nematodes. These embodiments are described in detail below.

Test compounds include any compound in general. Preferred test compounds are soluble in aqueous solution and thus conducive to typical biological assay conditions. In certain embodiments, test compounds are selected from any chemical in a library, for example, as maintained by a pharmaceutical or other company. In certain embodiments, test compounds, include proteins, glycoproteins, polypeptides, glycopeptides, amino acids, nucleic acids of any variety, including DNA, RNA, peptide nucleic acid (PNA), carbohydrates, fatty acids, lipids, etc. In certain embodiments the test compound includes any biologically active molecule.

Test compounds are administered to nematodes by any desirable method for determining which of the test compounds has an inhibitory activity on nematode fertility, female sexual maturation, or other activity described herein. For example, the test compound can be microinjected, co-injected, incubated, or fed to the nematodes. The assay measures the ability of specific test compounds to inhibit MSP stimulation of oocyte maturation, gonadal sheath cell contraction, and ovulation using optical monitoring. In addition to ovulation, laying or releasing of oocytes or embryos from the organism can be monitored optically and used as an endpoint of test compound activity. The optical monitoring can be enhanced using labeling reagents, such as fluorescent, radioactive, or enzymatic labels. These labels can be attached using standard chemistry known in the art to the test compound, a sperm, a major sperm protein, the oocyte, a sheath cell, etc.

Methods for monitoring the FSM by video microscopy are disclosed herein. Other methods for monitoring the FSM can include by radiolabel assay, fluorescent assay, etc. (Miller *et al.*, Science 2001).

Inhibition of FSM generally refers to a reduction or termination in rate of an FSM event, in certain preferred embodiments. In other embodiments, inhibition means reduction in reproductive success, fecundity, etc. In other preferred embodiments, inhibition results in control of a population of nematodes including a free-living, parasitic, terrestrial, or an aquatic nematodes population.

17.0 Assay for Identifying Inhibitors of MSP Signaling

As described herein, an object of the present invention is to provide assays for screening test compounds to identify anti-nematode agents. In certain embodiments, the agents will be inhibitors of female nematode fertility. In certain embodiments, the agents will be inhibitors of an MSP signal transduction. Such

agents generally interfere with nematode fertility and are useful as agents for control of nematodes including free-living and animal and plant parasitic nematodes. Certain embodiments of screening assays for inhibitors of MSP signal transduction follow.

5 18.0 Mutant Nematode Strains

In general, MSP protein is administered to a mutant hermaphrodite or female nematode strain that does not produce sperm (*e.g.*, mutants in *fog-1*, *fog-2*, *fog-3*, *fem-1*, *fem-2*, *fem-3*, or *gld-1*(Fog). The MSP protein can be administered, for example, by microinjection into the uterus of the mutant hermaphrodite or female
10 nematode strain. Such strains are available from the *C. elegans* Genetic Center or natural isolates of gonochoristic species. In embodiments that use microinjection, the technique is carried out according to standard practice (*e.g.*, see LaMunyon and Ward, Genetics (1994) 138:689-692, incorporated herein by reference). Female
15 nematode sexual maturation, such as oocyte maturation, sheath cell contraction, and ovulation are generally observed optically. Certain methods are described by McCarter *et al.*, *supra*.

19.0 Wild-Type Nematode Strains

In general, methods for screening test compounds for identifying factors that inhibit nematode fertility, and preferably that inhibit female sexual maturation,
20 can be administered to wild-type nematodes and the effect of the test compounds is usually monitored optically. Typically, the test compounds can be co-injected, incubated, or fed to nematodes. Ordinarily the endpoint of the assay measures the ability of compounds to inhibit MSP stimulation of oocyte maturation, gonadal sheath cell contraction, and ovulation as described above.

20.0 Transgenic Nematode Strains

Nematode strains that ectopically express MSP (including in non-spermatogenic tissues) can be used in methods for screening test factors to identify anti-nematode agents. Transgenic nematodes expressing MSP are generated using standard methods (*e.g.*, Methods in Cell Biology, ed. H. Epstein and D. Shakes, San Diego Academic Press, 452-482, incorporated by reference). Inhibitor compounds are, for example, incubated with or fed to the transgenic nematodes. The assay measures the ability of compounds to inhibit nematode fertility including, but not limited to: MSP stimulation of oocyte maturation, gonadal sheath cell contraction, and ovulation as described above. Typically, the inhibition of nematode fertility is measured optically. Test factors that inhibit MSP signal transduction will inhibit the nematode female sexual maturation. In addition, most transgenic strains produce different amounts of the transgenic factor, as is known in the art. Thus, nematodes that transgenically express varying amounts of MSP can be utilized to determine anti-nematode agent concentrations that are optimized for use on a particular nematode given that different nematodes express varying levels of MSP in the wild.

21.0 MSP Binding Assay

Compounds are screened for MSP binding affinity. Panels of candidate molecules are affixed to a matrix, for example microtitre wells, using standard methods. Labeled MSP protein, such as fluorescently, radioactively, or enzymatically linked MSP protein, is incubated with the compounds attached to the matrix, and then washed off (under conditions that remove unbound labeled MSP protein). Compounds which bind MSP are recognized by retention of the label (for example, optical recognition). Alternatively, MSP protein is affixed to a matrix, for

example microtitre wells, and incubated with labeled test compounds, such as fluorescently, radioactively, or enzymatically linked compounds, and then washed off, (under conditions that remove unbound labeled compound). Compounds which bind MSP are recognized by retention of the label.

5 In certain embodiments, compounds which bind MSP are then tested for the ability to block MSP signaling, for example by using bio-assays described herein. Compounds that inhibit or block nematode reproduction or fertility are anti-nematode agents. In certain embodiments, the anti-nematode agents are used to treat parasitic nematode infections in plants and animals by administering a therapeutically effective amount of the anti-nematode agent to the plant or animal to inhibit, or in certain cases to virtually block, nematode reproduction in the infected plant or animal.

22.0 Regulation of MSP protein to protein interactions

10
15
20
25
Compounds are screened for the ability to regulate protein to protein interactions of MSP. For example, MSP is known to exist in monomeric and dimeric forms. Thus, test compounds are screened in biological assays to identify factors that prevent dimerization, multimerization (complexes with two or more MSP subunits), and for factors that prevent multimers from dissociating into monomers. The effect test compounds on multimer formation can be determined by incubating the test compound with the MSP under multimer associating and dissociating conditions. These samples can be tested for biological activity in regard to nematode fertility as described herein. Multimer and monomer formation and dissociation can be monitored by techniques known in the art. For example, SDS versus native gel electrophoresis (polyacrylamide gel electrophoresis), electrospray mass spectroscopy, and gel exclusion.

In certain embodiments, compounds which regulate multimerization of MSP (formation and dissociation of multimers/monomers) are then tested for the ability to block MSP signaling. For example by using biological assays measuring nematode female sexual maturation as described herein. Compounds that inhibit nematode reproduction are anti-nematode agents. In certain embodiments, the anti-nematode agents are used to treat parasitic nematode infections in plants and animals by administering a therapeutically effective amount of the anti-nematode agent to the plant or animal to inhibit, or in certain cases to virtually block, nematode reproduction in the infected plant or animal.

23.0 Certain Nematode Varieties

Nematoda includes the roundworms and threadworms, and comprises a phylum of generally smooth-skinned, unsegmented worms with a long cylindrical body shape tapered at the ends; the phylum includes free-living and parasitic forms both aquatic and terrestrial (adapted from Academic Press Dictionary of Science and Technology).

Table 2, below, provides a listing of the common name and scientific name of a multitude of nematode varieties. MSP genes and proteins can be derived from these or other nematode varieties and strains for use in conjunction with the present invention (*e.g.*, in a screening assay). Also, parasitic nematode infections of these or other types of nematodes may be treated by anti-nematode agents described herein or identified as described herein. This list is not meant to be limited on the scope of the invention, but merely to be exemplary of types of nematode. Animal parasitic nematodes are also described in supplementary materials appended to this provisional application.

Table 2.

Common Name	Nematode Genus and species
African spiral nematode	<i>Helicotylenchus africanus</i>
Alfalfa root nematode	<i>Heterodera goettingiana</i>
Almond cyst nematode	<i>Heterodera amygdali</i>
Amaranth cyst nematode	<i>Cactodera amaranthi</i>
American dagger nematode	<i>Xiphinema americanum</i>
Amu-Darya nematode	<i>Heterodera oxiana</i>
Apple cyst nematode	<i>Globodera mali</i>
Apple root-knot nematode	<i>Meloidogyne mali</i>
Awl nematodes	<i>Dolichodorus</i> spp.
Banana meadow nematode	<i>Pratylenchus coffeae</i>
Banana nematode	<i>Pratylenchus musicola</i>
Banana root-lesion nematode	<i>Pratylenchus coffeae</i>
Banana spiral nematode	<i>Helicotylenchus multicinctus</i>
Banana-root nematode	<i>Radopholus similis</i>
Barley cyst nematode	<i>Heterodera hordecalis</i>
Barley root-knot nematode	<i>Meloidogyne nassi</i>
Beachgrass root-knot nematode	<i>Meloidogyne sasseri</i>
Beer nematode	<i>Panagrellus silusiae</i>
Beet nematode	<i>Heterodera schachtii</i>
Beet stem nematode	<i>Ditylenchus dipsaci</i>
Begonia leaf nematode	<i>Aphelenchoides fragariae</i>
Bentgrass nematode	<i>Anguina agrostis</i>
Bermudagrass cyst nematode	<i>Heterodera cardiolata</i>

Inventors: Greenstein and Miller
 Attorney Docket: N-7088-MJM
 Customer No. 23456

Birch cyst nematode	<i>Cactodera betulae</i>
Black currant nematode	<i>Aphelenchoides ritzemabosi</i>
Blueberry root-knot nematode	<i>Meloidogyne carolinensis</i>
Boxwood spiral nematode	<i>Rotylenchus buxophilus</i>
Brassica root eelworm	<i>Heterodera cruciferae</i>
Brassica root nematode	<i>Heterodera cruciferae</i>
Brazilian root-knot nematode	<i>Meloidogyne exigua</i>
Brazilian root-knot nematode	<i>Meloidogyne inornata</i>
British root-knot nematode	<i>Meloidogyne artiellia</i>
British spiral nematode	<i>Scutellonema brachyurum</i>
Buckwheat cyst nematode	<i>Heterodera graduni</i>
Bud and leaf nematodes	<i>Aphelenchoides</i> spp.
Bud and stem nematode	<i>Ditylenchus dipsaci</i>
Bulb and stem nematodes	<i>Ditylenchus</i> spp.
Bulb nematode	<i>Ditylenchus dipsaci</i>
Bulb or stem nematodes	<i>Ditylenchus</i> spp.
Burrowing nematode	<i>Radopholus similis</i>
Burrowing nematodes	<i>Radopholus</i> spp.
Cabbage cyst nematode	<i>Heterodera cruciferae</i>
Cabbage nematode	<i>Heterodera cruciferae</i>
Cabbage root nematode	<i>Heterodera cruciferae</i>
Cactus cyst nematode	<i>Cactodera cacti</i>
Cajanus cyst nematode	<i>Heterodera cajani</i>
California dagger nematode	<i>Xiphinema index</i>
California meadow nematode	<i>Pratylenchus neglectus</i>

Inventors: Greenstein and Miller
 Attorney Docket: N-7088-MJM
 Customer No. 23456

California root-lesion nematode	<i>Pratylenchus neglectus</i>
California sessile nematode	<i>Cacopaurus epacris</i>
Camel thorn cyst nematode	<i>Heterodera oxiana</i>
Camellia root-knot nematode	<i>Meloidogyne camelliae</i>
Canadian root-knot nematode	<i>Meloidogyne microtyla</i>
Carnation pin nematode	<i>Paratylenchus curvatus</i>
Carnation pin nematode	<i>Paratylenchus dianthus</i>
Carolina spiral nematode	<i>Scutellonema brachyurum</i>
Carrot cyst nematode	<i>Heterodera carotae</i>
Carrot root nematode	<i>Heterodera carotae</i>
Cereal cyst nematode	<i>Heterodera avenae</i>
Cereal cyst nematode	<i>Heterodera latipons</i>
Cereal root nematode	<i>Heterodera avenae</i>
Cereal root-knot nematode	<i>Meloidogyne nassi</i>
Cereals root eelworm	<i>Heterodera major</i>
Cereals root nematode	<i>Heterodera avenae</i>
Chamber's dagger nematode	<i>Xiphinema chambersi</i>
Christie's spiral nematode	<i>Scutellonema christiei</i>
Christie's stubby root nematode	<i>Trichodorus christiei</i>
Chrysanthemum foliar nematode	<i>Aphelenchoides ritzemabosi</i>
Chrysanthemum leaf nematode	<i>Aphelenchoides ritzemabosi</i>
Chrysanthemum nematode	<i>Aphelenchoides ritzemabosi</i>
Citrus nematode	<i>Tylenchulus semipenetrans</i>
Citrus ring nematode	<i>Criconemoides citri</i>
Citrus root nematode	<i>Tylenchulus semipenetrans</i>

Inventors: Greenstein and Miller
 Attorney Docket: N-7088-MJM
 Customer No. 23456

Citrus root-knot nematode	<i>Meloidogyne indica</i>
Citrus spine nematode	<i>Criconema civellae</i>
Clover cyst nematode	<i>Heterodera trifolii</i>
Clover root nematode	<i>Heterodera trifolii</i>
Clover stem nematode	<i>Ditylenchus dipsaci</i>
Cobb's awl nematode	<i>Dolichodorus heterocephalous</i>
Cobb's lance nematode	<i>Hoplolaimus galeatus</i>
Cobb's meadow nematode	<i>Pratylenchus penetrans</i>
Cobb's ring nematode	<i>Criconemoides simile</i>
Cobb's root lesion nematode	<i>Pratylenchus penetrans</i>
Cobb's root-knot nematode	<i>Nacobbus batatiformis</i>
Cobb's spiral nematode	<i>Helicotylenchus multicinctus</i>
Cobb's stubby root nematode	<i>Trichodorus primitivus</i>
Coconut nematode	<i>Rhadinaphelenchus cocophilus</i>
Coconut palm nematode	<i>Rhadinaphelenchus cocophilus</i>
Cocopalm nematode	<i>Rhadinaphelenchus cocophilus</i>
Coffee meadow nematode	<i>Pratylenchus coffeae</i>
Coffee root-knot nematode	<i>Meloidogyne exigua</i>
Coffee root-lesion nematode	<i>Pratylenchus coffeae</i>
Columbia nematode	<i>Hoplolaimus columbus</i>
Columbia root-knot nematode	<i>Meloidogyne chitwoodi</i>
Corn cyst nematode	<i>Heterodera zae</i>
Corn meadow nematode	<i>Pratylenchus zae</i>
Corn root-lesion nematode	<i>Pratylenchus zae</i>
Cotton root-knot nematode	<i>Meloidogyne incognita acrita</i>

Inventors: Greenstein and Miller
Attorney Docket: N-7088-MJM
Customer No. 23456

Cowpea cyst nematode	<i>Heterodera vigni</i>
Crown-headed lance nematode	<i>Hoplolaimus tylenchiformis</i>
Currant nematode	<i>Aphelenchoides ribes</i>
Cyperus cyst nematode	<i>Heterodera moths</i>
Cyst nematodes	<i>Globodera</i> spp.
Cyst nematodes	<i>Heterodera</i> spp.
Cyst-forming nematodes	<i>Heterodera</i> spp.
Cystoid body nematodes	<i>Meloidoderita</i> spp.
Cystoid nematodes	<i>Meloidodera</i> spp.
Dagger nematodes	<i>Xiphinema</i> spp.
De Man's meadow nematode	<i>Pratylenchus pratensis</i>
De Man's root-lesion nematode	<i>Pratylenchus pratensis</i>
Dock cyst nematode	<i>Heterodera rosii</i>
Douglas Fir nematode	<i>Nacobboldera chitwoodi</i>
Ear-cockle nematode	<i>Anguina tritici</i>
Estonian cyst nematode	<i>Cactodera estonica</i>
Eucalypt cystoid nematode	<i>Cryphodera eucalypti</i>
European dagger nematode	<i>Xiphinema diversicaudatum</i>
False root-knot nematode of sugar beets	<i>Nacobbus batatiformis</i>
False root-knot nematode	<i>Nacobbus</i> spp.
Fern nematode	<i>Aphelenchoides fragariae</i>
Fern nematode	<i>Aphelenchoides olesistus</i>
Fescue leaf gall nematode	<i>Anguina graminis</i>
Ficus cyst nematode	<i>Heterodera fici</i>
Fig cyst nematode	<i>Heterodera fici</i>

Fig pin nematode	<i>Paratylenchus hamatus</i>
Fig spine nematode	<i>Criconema decalineatum</i>
Foliar nematodes	<i>Aphelenchoides</i> spp.
Galeopsis cyst nematode	<i>Heterodera galeopsidis</i>
Galeopsis root nematode	<i>Heterodera galeopsidis</i>
Gall-forming nematodes	<i>Meloidogyne</i> spp.
Godfrey's meadow nematode	<i>Pratylenchus brachyurus</i>
Godfrey's root-lesion nematode	<i>Pratylenchus brachyurus</i>
Gold-plated nematode	<i>Globodera rostochiensis</i>
Golden nematode	<i>Globodera rostochiensis</i>
Golden nematode of potato	<i>Globodera rostochiensis</i>
Grass cyst nematode	<i>Punctodera punctata</i>
Grass root-gall nematode	<i>Subanguina radiculicola</i>
Grass sheath nematode	<i>Hemicycliophora similis</i>
Grass spiral nematode	<i>Helicotylenchus erythrinae</i>
Great root nematode	<i>Heterodera avenae</i>
Hairy-gall nematode	<i>Nacobbus batatiformis</i>
Heart-shaped cyst nematode	<i>Heterodera cardiolata</i>
Hop cyst nematode	<i>Heterodera humuli</i>
Hop nematode	<i>Heterodera humuli</i>
Hop root nematode	<i>Heterodera humuli</i>
Horsenettle cyst nematode	<i>Globodera tabacum virginiae</i>
Indian root-knot nematode	<i>Meloidogyne brevicauda</i>
Iris nematode	<i>Ditylenchus destructor</i>
Japanese cyst nematode	<i>Heterodera elachista</i>

Inventors: Greenstein and Miller
Attorney Docket: N-7088-MJM
Customer No. 23456

Javanese root-knot nematode	<i>Meloidogyne javanica</i>
Kansas cyst nematode	<i>Heterodera longicolla</i>
Kidney-shaped nematode	<i>Rotylenchulus reniformis</i>
Kikuyu grass nematode	<i>Meloidogyne kikuyuensis</i>
Knapweed nematode	<i>Mesoanguina picridis</i>
Knawel cyst nematode	<i>Heterodera scleranthii</i>
Knotweed cyst nematode	<i>Cactodera weissi</i>
Kona coffee root-knot nematode	<i>Meloidogyne konaensis</i>
Lance nematodes	<i>Hoplolaimus</i> spp.
Lesion nematodes	<i>Pratylenchus</i> spp.
Lespedeza cyst nematode	<i>Heterodera lespedezae</i>
Lucerne cyst nematode	<i>Heterodera medicaginis</i>
Maple root-knot nematode	<i>Meloidogyne ovalis</i>
Meadow nematodes	<i>Pratylenchus</i> spp.
Mediterranean cereal cyst nematode	<i>Heterodera latipons</i>
Milfoil cyst nematode	<i>Globodera millefolii</i>
Motha cyst nematode	<i>Heterodera mothi</i>
Mushroom nematode	<i>Aphelenchoides composticola</i>
Mushroom spawn nematode	<i>Ditylenchus myceliophagus</i>
Needle nematodes	<i>Longidorus</i> spp.
Nettle cyst nematode	<i>Heterodera urticae</i>
Nigerian dagger nematode	<i>Xiphinema nigeriense</i>
Northern root-knot nematode	<i>Meloidogyne hapla</i>
Nutgrass cyst nematode	<i>Heterodera cyperi</i>
Oak root-knot nematode	<i>Meloidogyne querciana</i>

Oak sheathoid nematode	<i>Hemicriconemoides biformis</i>
Oat cyst nematode	<i>Heterodera avenae</i>
Oat cyst nematode	<i>Heterodera major</i>
Oat nematode	<i>Heterodera avenae</i>
Oat root nematode	<i>Heterodera avenae</i>
Onion stem nematode	<i>Ditylenchus dipsaci</i>
Osborne's cyst nematode	<i>Globodera tabacum solanacearum</i>
Pacific dagger nematode	<i>Xiphinema radicicola</i>
Pea cyst nematode	<i>Heterodera goettingiana</i>
Pea root eelworm	<i>Heterodera goettingiana</i>
Pea root nematode	<i>Heterodera goettingiana</i>
Peanut root-knot nematode	<i>Meloidogyne arenaria</i>
Persian sessile nematode	<i>Cacopaurus pestis</i>
Phlox stem nematode	<i>Ditylenchus dipsaci</i>
Pigeon pea cyst nematode	<i>Heterodera cajani</i>
Pin nematodes	<i>Paratylenchus</i> spp.
Pine cystoid nematode	<i>Meloidodera floridensis</i>
Pine sheathoid nematode	<i>Hemicriconemoides floridensis</i>
Pine sting nematode	<i>Belonolaimus gracilis</i>
Pine wood nematode	<i>Bursaphelenchus xylophilus</i>
Potato cyst eelworm	<i>Globodera rostochiensis</i>
Potato cyst nematode	<i>Globodera pallida</i>
Potato cyst nematode	<i>Globodera rostochiensis</i>
Potato nematode	<i>Globodera rostochiensis</i>
Potato root eelworm	<i>Globodera rostochiensis</i>

Inventors: Greenstein and Miller
 Attorney Docket: N-7088-MJM
 Customer No. 23456

Potato root nematode	<i>Globodera rostochiensis</i>
Potato rot nematode	<i>Ditylenchus destructor</i>
Potato tuber eelworm	<i>Ditylenchus destructor</i>
Potato tuber nematode	<i>Ditylenchus destructor</i>
Pseudo root-knot nematode	<i>Hypsoperine graminis</i>
Ramie pin nematode	<i>Paratylenchus elachistus</i>
Red ring nematode	<i>Rhadinaphelenchus cocophilus</i>
Reniform nematode	<i>Rotylenchulus reniformis</i>
Reniform nematodes	<i>Rotylenchulus</i> spp.
Rice blind root nematodes	<i>Hirschmanniella</i> spp.
Rice cyst nematode	<i>Heterodera oryzae</i>
Rice nematode	<i>Aphelenchoides oryzae</i>
Rice root nematode	<i>Hirschmanniella oryzae</i>
Rice root-knot nematode	<i>Meloidogyne graminicola</i>
Rice stem nematode	<i>Ditylenchus angustus</i>
Rice stunt nematode	<i>Tylenchorhynchus martini</i>
Rice white-tip nematode	<i>Aphelenchoides besseyi</i>
Rice-root nematode	<i>Radopholus oryzae</i>
Ring nematodes	<i>Criconema</i> spp.
Ring nematodes	<i>Criconemoides</i> spp.
Root nematodes	<i>Heterodera</i> spp.
Root nematodes	<i>Hirschmanniella</i> spp.
Root-gall nematodes	<i>Meloidogyne</i> spp.
Root-knot nematodes	<i>Meloidogyne</i> spp.
Root-lesion nematodes	<i>Pratylenchus</i> spp.

Round cystoid nematode	<i>Thecavermiculatus andinus</i>
Rubber cyst nematode	<i>Heterodera fici</i>
Rumex cyst nematode	<i>Heterodera rumicis</i>
Scribner's lesion nematode	<i>Pratylenchus scribneri</i>
Scribner's meadow nematode	<i>Pratylenchus scribneri</i>
Scribner's root-lesion nematode	<i>Pratylenchus scribneri</i>
Sedge cyst nematode	<i>Heterodera cyperi</i>
Seed gall nematode	<i>Afrina wevelli</i>
Seed gall nematodes	<i>Anguina</i> spp.
Seed-gall nematode	<i>Anguina tritici</i>
Seinhorst's stubby root nematode	<i>Trichodorus pachydermis</i>
Sessile nematodes	<i>Cacopaurus</i> spp.
Seville root-knot nematode	<i>Meloidogyne hispanica</i>
Sheath nematodes	<i>Hemicycliophora</i> spp.
Sheathoid nematodes	<i>Hemicriconemoides</i> spp.
Shoot gall nematodes	<i>Anguina</i> spp.
Smooth-headed lesion nematode	<i>Pratylenchus brachyurus</i>
Smooth-headed meadow nematode	<i>Pratylenchus leiocephalus</i>
Smooth-headed nematode	<i>Pratylenchus brachyurus</i>
Sorghum root-knot nematode	<i>Meloidogyne acronea</i>
Sour paste nematode	<i>Panagrellus redivivus</i>
South African pin nematode	<i>Paratylenchus curvittatus</i>
Southern root-knot nematode	<i>Meloidogyne incognita</i>
Sowthistle cyst nematode	<i>Heterodera sonchophila</i>
Soybean cyst nematode	<i>Heterodera glycines</i>

Inventors: Greenstein and Miller
Attorney Docket: N-7088-MJM
Customer No. 23456

Spear nematodes	<i>Dorylaimus</i> spp.
Spine nematodes	<i>Criconema</i> spp.
Spiral nematodes	<i>Helicotylenchus</i> spp.
Spiral nematodes	<i>Rotylenchus</i> spp.
Spiral nematodes	<i>Scutellonema</i> spp.
Spring crimp nematode	<i>Aphelenchoides fragariae</i>
Spring dwarf nematode	<i>Aphelenchoides besseyi</i>
Steiner's spiral nematode	<i>Helicotylenchus dihystera</i>
Stem gall nematode	<i>Pterotylenchus cecidogenus</i>
Stem nematode	<i>Ditylenchus dipsaci</i>
Sting nematode	<i>Belonolaimus gracilis</i>
Sting nematode	<i>Belonolaimus longicaudatus</i>
Sting nematodes	<i>Belonolaimus</i> spp.
Strawberry bud nematode	<i>Aphelenchoides besseyi</i>
Strawberry bud nematode	<i>Aphelenchoides fragariae</i>
Strawberry foliar nematode	<i>Aphelenchoides fragariae</i>
Strawberry nematode	<i>Aphelenchoides fragariae</i>
Stubby root nematode	<i>Trichodorus christiei</i>
Stubby root nematode	<i>Trichodorus kurumeensis</i>
Stubby root nematodes	<i>Paratrichodorus</i> spp.
Stubby root nematodes	<i>Trichodorus</i> spp.
Stunt nematode	<i>Tylenchorhynchus claytoni</i>
Stunt nematodes	<i>Tylenchorhynchus</i> spp.
Stylet nematodes	<i>Tylenchorhynchus</i> spp.
Sugar beet cyst nematode	<i>Heterodera schachtii</i>

Inventors: Greenstein and Miller
 Attorney Docket: N-7088-MJM
 Customer No. 23456

Sugar beet nematode	<i>Heterodera schachtii</i>
Sugar cane cyst nematode	<i>Heterodera sacchari</i>
Sugar cane cyst nematode	<i>Heterodera schachtii</i>
Sugar cane stylet nematode	<i>Tylenchorhynchus martini</i>
Summer dwarf nematode	<i>Aphelenchoides fragariae</i>
Sycamore root-knot nematode	<i>Meloidogyne platani</i>
Tadzhik cyst nematode	<i>Heterodera tadshikistanica</i>
Tadzhik cystoid nematode	<i>Meloidodera tadshikistanica</i>
Tadzhik root-knot nematode	<i>Meloidogyne tadshikistanica</i>
Tarjan's sheath nematode	<i>Hemicycliophora parvana</i>
Tea root-knot nematode	<i>Meloidogyne brevicauda</i>
Teasel nematode	<i>Ditylenchus dipsaci</i>
Tesselate stylet nematode	<i>Tylenchorhynchus claytoni</i>
Thames' root-knot nematode	<i>Meloidogyne thamesi</i>
Thorne's cyst nematode	<i>Cactodera thornei</i>
Thorne's lance nematode	<i>Rotylenchus uniformis</i>
Thorne's meadow nematode	<i>Pratylenchus thornei</i>
Thorne's needle nematode	<i>Longidorus sylphus</i>
Thorne's root-lesion nematode	<i>Pratylenchus thornei</i>
Tobacco cyst nematode	<i>Globodera tabacum</i>
Tobacco stunt nematode	<i>Tylenchorhynchus claytoni</i>
Tulip root nematode	<i>Ditylenchus dipsaci</i>
Turf spiral nematode	<i>Rotylenchus christiei</i>
Turkmen cyst nematode	<i>Heterodera turcomanica</i>
Ustinov cyst nematode	<i>Heterodera ustinovi</i>

Valentine cyst nematode	<i>Heterodera cardiolata</i>
Vinegar eels	<i>Turbatrix aceti</i>
Vinegar nematode	<i>Turbatrix aceti</i>
Walnut meadow nematode	<i>Pratylenchus vulnus</i>
Walnut root-lesion nematode	<i>Pratylenchus vulnus</i>
Walnut sessile nematode	<i>Cacopaurus pestis</i>
Wesson's sheathoid nematode	<i>Hemicriconemoides wessoni</i>
West African spiral nematode	<i>Scutellonema blaberum</i>
Wheat cyst nematode	<i>Heterodera latipons</i>
Wheat gall nematode	<i>Anguina tritici</i>
White-tip nematode	<i>Aphelenchoides besseyi</i>
Willow cyst nematode	<i>Heterodera salixophila</i>
Yam nematode	<i>Scutellonema bradys</i>
Yarrow cyst nematode	<i>Globodera achilleae</i>
Zimmerman's spiral nematode	<i>Helicotylenchus erythrinae</i>
Zoysia spine nematode	<i>Criconema spinalineatum</i>

24.0 Treating a parasitic nematode infection

In certain embodiments of the present invention, a parasitic nematode infection is treated in an infected organism (including plants and animals). A preferred method of treating a parasitic nematode infection is to inhibit nematode fertility or reproduction in the infected animal. In general, this is done by administering a therapeutically effective amount of an anti-nematode agent as described herein which disrupts a biological activity of MSP related to female

nematode sexual maturation. The anti-nematode agent can be identified as described in the present invention.

In certain embodiments, a method of inhibiting a reproduction of a nematode is provided, comprising inhibiting a signal transduction of a major sperm protein of the nematode, wherein the signal transduction stimulates a female sexual maturation.

In certain embodiments, MSP signal transduction is inhibited by a method comprising administering an MSP-specific antibody (Several MSP-specific antibodies have been described in the art. For example, see, Klass, M. R., and Hirsh, D. 1981. Sperm isolation and biochemical analysis of the major sperm protein from *Caenorhabditis elegans*. Dev. Biol. 84, 299-312, incorporated herein by reference). (In certain examples, the MSP-specific antibody can be administered by solublizing the antibody in the nematode's environment or by microinjection into the uterus of the nematode. Without being bound to mechanism or theory, these antibodies bind MSP *in vivo* and inhibit MSP-mediated signaling. Experiments are contemplated wherein hermaphrodite oocyte maturation and sheath cell contraction rates will be compared to hermaphrodites injected with an antibody which does not bind MSP (a suitable antibody for a negative control experiment).

In certain embodiments, MSP signal transduction is inhibited by administering a vaccine (especially in the case of treating an animal) wherein the vaccine is developed to an MSP protein or fragment thereof. Any variety of MSP protein, or fragment thereof, can be used in vaccine development. Many nematode types are described herein and the MSP or MSPs isolated therefrom may be used. Vaccine development protocols are well known.

In certain embodiments the identified anti-nematode agent is applied to crops including by spraying a field to distribute the agent. The agent may gain access

directly to the nematode or exist in the soil, water, food or general environment of the nematode. The agent may also be transferred to the nematode from a plant or animal.

25.0 Pharmaceutical formulations

5 In certain embodiments, the preferred method of administering a biologically active molecule (such as MSP or an anti-nematode agent) is in combination with an excipient (a pharmaceutically acceptable carrier). The combination of at least one pharmaceutically acceptable carrier and at least one biologically active molecule is referred to herein as a pharmaceutical formulation.

10 The particular excipient is not believed to be critical as long as it is compatible with the biological activity of the biologically active molecule and compatible with administration to the subject, especially plants, animals, human, and other mammals. The choice of excipient depends on the nature of the treatment being administered and the biologically active molecule. The pharmaceutical formulation can be applied to the surface of the organism being treated for a parasitic nematode infection or injected into the local tissue either in one application or multiple applications. The pharmaceutical formulation can be combined with additional inert or carrier ingredients and used as a topical salve. The pharmaceutical formulation may also be aerosolized and administered through
20 the lungs.

In certain preferred embodiments, a pharmaceutical formulation is provided along with a method of applying a metered amount of the formulation. For example, if a syringe may include unit markings on the barrel of the syringe. Typically a syringe will also include a needle and a plunger to form a device effective for
25 administration by injection. The particular choice of pharmaceutically acceptable

carrier can be made by one with skill in the art, such as a treating physician, veterinarian, farmer, or extension service personnel.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic
5 and absorption delaying agents and the like that are compatible with the biologically active molecule(s) and with administration to the organism being treated.

In certain embodiments, the pharmaceutical formulations of the present invention are advantageously administered either as liquid solutions or suspensions. Solid forms may be solubilized or suspended in liquid prior to application or injection. These preparations also may be emulsified. In certain
10 embodiments, a typical composition comprises about 50 mg or up to about 100 mg of human serum albumin per milliliter of phosphate buffered saline. Other pharmaceutically acceptable carriers include aqueous solutions, salts, preservatives, buffers and the like. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil, and organic esters, such as theyloleate. Aqueous carriers include water, alcoholic/aqueous solutions, and saline solutions including sodium chloride, Ringer's dextrose, etc. Preservatives include
15 antimicrobial agents, anti-oxidants, chelating agents and inert gases. The pH and exact concentration of the various components in the pharmaceutical formulation are adjusted according to well known parameters using well known buffering and dilution agents.

20 26.0 Production of Recombinant MSP Containing Vectors

Recombinant MSP bacterial strains were produced by cloning MSP-142 and
25 MSP-38 into the pQe-30 6-His vector from Qiagen. Primers specific for MSP were

made that contained a 5' BamHI site (5' primer) or a 5' HindIII (3' primer) followed by the respective MSP-coding sequences. MSP-38 and MSP-142 were amplified by PCR, cut with BamHI and HindIII, and ligated into the pQe-30 vector (FIG. 6) which was also cut with BamHI and HindIII. This strategy generated a vector
5 containing an IPTG-inducible promoter followed by an initiator methionine, an N-terminal 6-His tag, and the respective MSP-38 or MSP-142 coding sequences. This construct was then transformed into M15(pREP4) bacterial cells and vector-containing colonies were selected with LB medium containing Ampicillin and Kanamycin. MSP-containing colonies were grown overnight and then MSP
10 expression was induced for 4 hours with 1 mM IPTG. Induced bacteria were pelleted, lysed, and purified using a NiNTA agarose column, which binds the 6-His tag. 6-His purification is known in the art.

27.0 Biological Functional Equivalents of Polynucleotides and Polypeptides

As is known to one with skill in the art, the biological function or activity of a gene product may not correspond directly to an absolute polynucleotide or polypeptide sequence of the gene product. Therefore, the inventor specifically contemplates that alterations to sequences provided herein may be made or used wherein the altered sequences, or methods of use thereof, are equivalent to sequences, or methods of use thereof, and are within the spirit and scope of the
15 present invention. These equivalent sequences are referred to as biologically functional equivalents, or simply as functional equivalents. Functional equivalents can include, but are not limited to: conservatively modified variants, degeneracy of the nucleic acid code, polymorphisms, certain insertions and deletions, and certain length variants. Methods for altering sequence residues and testing the altered
20

sequences for function or activity are known in the art or described herein. These alterations may be natural or made by the "hand of man".

At the nucleotide level, different codons can encode the same amino acid. In other words, the genetic code is degenerate (Alberts *et al.*, Molecular Biology of the Cell, (1989) 2nd Edition, Garland Publishing, Inc., and incorporated herein by reference). The terms "wobble" and "nucleic acid degeneracy" are used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine. Preferred human codons are provided in materials appended to this application. Codon preferences for other organisms also are well known to those of skill in the art (Wada *et al.*, 1990, *supra*). Thus, one with skill in the art knows that two different polynucleotides can encode identical polypeptide sequences due to codon wobble.

It is understood in the art that amino acid and nucleic acid sequences may include additional residues, such as additional N-terminal or C-terminal amino acids or 5' or 3' sequences, and yet still be essentially as set forth in one of the sequences disclosed herein; so long as the sequence meets the criteria set forth herein, including the maintenance of at least one biological protein activity where protein expression is concerned (MSP activity should include at least one type of stimulation of female nematode sexual maturation). The addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, *i.e.*, introns, which are known to occur within genes between coding regions (Alberts *et al.*, *supra*, incorporated herein by reference). Thus; about 1, 2, 3, 4, 5, 6, 7, or more than 7 amino acids could be added to a polypeptide and the polypeptide may still retain at least one biological activity. Or; about 1, 2, 3, 4, 5, 6, 7, or more than 7 nucleotides

could be added to a polynucleotide and expression products of the polynucleotide may still retain at least one biological activity.

It also is understood in the art that amino acid and nucleic acid residues may be removed from the N-terminal or C-terminal ends of polypeptide or 5' or 3' ends of polynucleotide sequences, and yet still be essentially as set forth in one of the sequences disclosed herein; so long as the sequence meets the criteria set forth herein, including the maintenance of at least one biological protein activity of where protein expression is concerned (in particular stimulating a female nematode sexual maturation with regard to MSP). The removal of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, *i.e.*, introns, which are known to occur within genes between coding regions (Alberts *et al.*, supra, incorporated herein by reference). Thus; about 1, 2, 3, 4, 5, 6, 7, or more than 7 amino acids could be removed from a polypeptide and the polypeptide may still retain at least one biological activity. Or, about 1, 2, 3, 4, 5, 6, 7, or more than 7 nucleotides could be removed from a polynucleotide and expression products of the polynucleotide may still retain at least one biological activity.

If desired, it is possible using techniques known to one with skill in the art, to include an intron in a recombinant polynucleotide sequence. For example, a bovine growth hormone (bGH) intron including splice sites may be added. In certain instances, the addition of an intron to a recombinant polynucleotide has been observed to increase expression of the encoded expression product in eukaryotic cells. It is understood that the addition of an intron may create a functionally equivalent sequence.

It is further understood in the art that insertions and deletions may be made within the amino acid and nucleic acid sequence, and yet still be essentially as set forth in one of the sequences disclosed herein; so long as the sequence meets the criteria set forth herein, including the maintenance of biological protein activity where protein expression is concerned (for MSP this should be a stimulation of at least one female nematode sexual maturation). It is preferred that the reading frame of a polynucleotide sequence be maintained, as is known in the art (Alberts *et al.*, supra, incorporated herein by reference).

Excepting intronic or flanking regions, and allowing for the degeneracy of the genetic code, sequences that have between about 70% and about 79%; or more preferably, between about 80% and about 89%; or more preferably, between about 90% and about 95% or more; or even more preferably, between about 96% and about 99%, or more of nucleotides being identical are homologous nucleic acids. Homologous sequences may be functionally defined as sequences that are capable of hybridizing to a nucleic acid segment under relatively stringent conditions. Suitable relatively stringent hybridization conditions are well known to those of skill in the art. In certain embodiments, relatively stringent hybridization conditions allow hybridization between sequences with about 70% homology or more, but disrupt binding between sequences with less than 70% homology. In certain embodiments, sequences that are considered "essentially as set forth" in a sequence listed herein are also biologically functional equivalents to the listed sequence if at least one biological activity is found in common.

At the protein level, peptide sequences that are essentially the same, in general, are capable of cross-reacting with antibody raised against the respective peptide factor. Methods for isolating, resolving, and analyzing protein/antibody

interactions are well known in the art including techniques such as SDS-PAGE and Western analysis.

10 The nucleic acid segments of the present invention, regardless of the length of the coding sequence itself, may be combined with other DNA sequences (one or more of each), such as promoters, polyadenylation signals, additional restriction
5 enzyme sites, multiple cloning sites, internal ribosome entry sites, introns, other coding segments, membrane transport sequences, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. Therefore, the terms "MSP gene" may also comprise any combination of associated control sequences. Furthermore, those skilled in the art of mutagenesis will appreciate that other analogs, as yet undisclosed or undiscovered, may be used to construct MSP analogs (mutants, variants, etc). Additional meaning
15 of biological functional equivalents, similarity, percent similarity, equivalents, substantially identical sequences, essentially the same, and essentially similar sequences and activities are described in U.S. Patent 5,922,688 to Hung *et al.*, incorporated herein by reference.

20 Naturally, the present invention also encompasses peptides and polypeptides (or the nucleic acid sequences that encode such peptides and polypeptides) that contain conservatively modified variants of sequences of interest, for example, a MSP sequence. One with skill in the art is able to determine conservative sequence modifications. In the case of a polypeptide, amino acid substitutions, such as those which might be employed in modifying a peptide, such as MSP, are generally based
25 on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like.

An analysis of the size, shape and type of the amino acid side-chain substituents reveals that arginine, lysine and histidine are all positively charged residues; that alanine, glycine and serine are all a similar size; and that phenylalanine, tryptophan and tyrosine all have a generally similar shape. Therefore, based upon these considerations, arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine; are defined herein as conservative amino acid changes or substitutions. In general, conservatively modified variants of a sequence may include one or more conservative amino acid change or substitution.

In making such changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte *et al.*, J. Mol. Biol. (1982) 157(1):105-32, incorporated herein by reference). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

It also is understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Patent 4,554,101 to Hopp,

incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, *i.e.* with a biological property of the protein. It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent protein.

As detailed in U.S. Patent 4,554,101, *supra*, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 \pm 1); glutamate (+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 \pm 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).

In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within \pm 2 is preferred, those which are within \pm 1 are particularly preferred, and those within \pm 0.5 are even more particularly preferred.

While discussion has focused on conservatively modified variant polypeptides and functionally equivalent polypeptides arising from amino acid changes, it will be appreciated that these changes may be effected by alteration of the encoding polynucleotide; taking into consideration also that the genetic code is degenerate and that two or more codons may code for the same amino acid.

28.0 Sequence Modification Techniques

Modifications to sequences, such as MSP sequences, may be made during chemical synthesis of the polymers (either nucleotide or peptide synthesis). It is believed, however, that site-directed mutagenesis of an encoding nucleic acid,

creating a suitably altered polynucleotide sequence is the most cost effective method of generating an altered polynucleotide sequence. Where the MSP protein is desired, then the mutated sequence may be expressed including in culture (*in vitro* or *ex vivo*) or *in vivo*.

5 Site-directed mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent proteins or peptides, through specific mutagenesis of the underlying DNA. Several methods for site directed mutagenesis are described in U.S. Patent 4,873,192 to Kunkel, incorporated herein by reference and in U.S. Patent 4,351,901 to Ball, incorporated
10 herein by reference. The technique further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired
15 mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 14 to about 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered. The primers can be selected by one
20 with ordinary skill in the art based upon information provided herein, including the Sequence Listings and Figures.

 The technique of site-specific mutagenesis is well known in the art as exemplified by publications (Adelman *et al.*, (1983) DNA 2(3)183-193, incorporated herein by reference). As will be appreciated, the technique typically employs a
25 phage vector which exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13

phage. These phage are readily commercially available and their use is well known to those skilled in the art. Double stranded plasmids are also routinely employed in site directed mutagenesis which eliminates the step of transferring the gene of interest from a plasmid to a phage. Kits for phage based site directed mutagenesis are commercially available. In addition PCR based methods which may, or may not, involve phage are known in the art and kits for such purposes are commercially available.

In certain known techniques, site-directed mutagenesis is performed by first obtaining a single-stranded vector or melting apart the two strands of a double stranded vector which includes within its sequence a DNA sequence which encodes the desired nucleotide, such as MSP. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically as is known to one of ordinary skill in the art. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as *Escherichia coli* (*E. coli*) polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement. Various selection methods that increase the percentage of specifically modified clones over wild-type are known and available commercially.

Kalderon *et al.* (1984) report several mutagenic methods which have proved useful in mutating the native LT gene. Specifically, Kalderon *et al.* teach deletion mutations by displacement-loop mutagenesis and by the random insertion of Eco RI linkers into the LT gene. Further, point mutation by deletion-loop mutagenesis is

taught. The reference also teaches screening procedures for determining the success of such mutations. The teachings of Kalderon *et al.* (1984) Virology 139(1)109-137 are incorporated herein by reference.

5 The preparation of sequence variants of the selected gene using site-directed mutagenesis is provided as a method of producing potentially useful nucleic acids and peptides (such as MSP and MSP variants) and is not meant to be limiting as there are other ways in which sequence variants of these nucleotide and peptides may be obtained. For example, recombinant vectors encoding the desired genes may be treated with mutagenic agents to obtain sequence variants for the mutagenesis of plasmid DNA using hydroxylamine or random mutagenesis may be performed using the PCR technique.

10 Sequence analysis of a potentially mutant nucleic acid sequence is carried out by methods known in the art, typically by either Sanger dideoxy sequencing (Sanger *et al.*, PNAS (1977) 74:5363-5467, incorporated herein by reference; U.S. Patent 15 4,871,929 to Barnes; and U.S. Patent 4,962,020 to Tabor *et al.*, each patent incorporated herein by reference) or automated sequencing (U.S. Patent 5,365,455 to Tibbetts *et al.*, incorporated herein by reference).

20 In addition to the MSP peptidyl compounds described herein, the inventors also contemplate that other sterically similar compounds may be formulated to mimic the key portions of the peptide structure. Such compounds may be used in the same manner as the peptides of the invention and hence are also functional equivalents. The generation of a structural functional equivalent may be achieved by the techniques of modeling and chemical design known to those of skill in the art. It will be understood that all such sterically similar constructs fall within the 25 scope of the present invention.

Livestock include, but are not limited to: horses, work horses, show horses, cattle, sheep, goats, and the like. Pets include, but are not limited to: dogs, cats, horses, birds, and the like.

EXAMPLES

Example 1

Large quantities of sperm (generally >108) are purified using a modification of methods developed by Klass and Hirsh (1981). Adult males are identified using synchronized cultures (Lewis and Flemming, 1995) of *fog-2(q71)*, which are 50% male and 50% female. Mutations in the *fog-2* gene block spermatogenesis in XX animals, transforming them into females, but have no effect on X0 animals, which are fertile males (Schedl and Kimble, 1988). Males are separated from females, larvae, and embryos based on size by sieving through NITEX screens of various pore sizes. The populations of males isolated in this way are generally >99% pure. To isolate sperm, males are placed between two PLEXIGLASS plates and smashed in a vice grip (The Home Depot, Inc.). Intact sperm are then purified from the carcasses by filtration through NITEX filters (20 micron pore size) and washed in M9 phosphate buffer (Sulston and Hodgkin, 1988) using several rounds of low speed centrifugation (*e.g.*, 10,000xg) and resuspension. Sperm-conditioned medium (SCM) is prepared by incubating purified sperm in M9 for different periods of time (1-12 h) and subsequently removing the sperm by centrifugation and filtration through a 0.2 micron filter. Microscopic analysis suggests that the sperm are not lysing during the incubation. Polyacrylamide gel electrophoresis (PAGE) further indicates that the sperm are not lysing during the incubation, but that a 14 kDa protein is enriched in SCM (FIG. 2).

REFERENCES

All references, articles, U.S. Patents, Non-U.S. Patents, exhibits and the like referred to herein, including those listed below or attached, are hereby incorporated herein by reference in their entirety.

5 Achanzar, W. E., and Ward, S. (1997). A nematode gene required for sperm vesicle fusion. *Journal of Cell Science* 110: 1073-1081.

Albertson, D. G. (1984). Formation of the first cleavage spindle in nematode embryos. *Developmental Biology* 101: 61-72.

10 Albertson, D. G., and Thomson, J. N. (1993). Segregation of holocentric chromosomes at meiosis in the nematode, *Caenorhabditis elegans*. *Chromosome Research* 1: 15-26.

Anderson, E., and Albertini, D. F. (1976). Gap junctions between the oocyte and companion follicle cells in the mammalian ovary. *Journal of Cell Biology* 71: 680-686.

15 Argon, Y., and Ward, S. (1980). *C. elegans* fertilization-defective mutants with abnormal sperm. *Genetics* 96: 413-433.

Aroian, R. V., Field, C., Pruliere, G., Kenyon, C., and Alberts, B. M. (1997). Isolation of actin-associated proteins from *Caenorhabditis elegans* oocytes and their localization in the early embryo. *EMBO Journal* 16: 1541-1549.

20 Aruffo, A., and Seed, B. (1987). Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. *Proceedings of the National Academy of Sciences U S A* 84: 8573-8577.

25 Austin, J., and Kimble, J. (1987). *glp-1* is required in the germ line for regulation of the decision between mitosis and meiosis in *C. elegans*. *Cell* 51: 589-599.

Barton, M. K., and Kimble, J. (1990). *fog-1*, a regulatory gene required for specification of spermatogenesis in the germ line of *Caenorhabditis elegans*. Genetics 125: 29-39.

Bashir, R., Britton, S., Strachan, T., Keers, S., Vafiadaki, E., Lako, M.,
5 Richard, I., Marchand, S., Bourg, N., Argov, Z., Sadeh, M., Mahjneh, I., Marconi, G.,
Passos-Bueno, M. R., Moreira, E. de S., Zatz, M., Beckmann, J. S., and Bushby, K.
(1998). A gene related to *Caenorhabditis elegans* spermatogenesis factor *fer-1* is
mutated in limb-girdle muscular dystrophy type 2B. Nature Genetics 20: 37-42.

Blaxter, M. (1998). *Caenorhabditis elegans* is a nematode. Science 282: 2041-
10 2046.

Boxem, M., Srinivasan, D. G., and van den Heuvel, S. (1999). The
Caenorhabditis elegans gene *ncc-1* encodes a cdc2-related kinase required for M
phase in meiotic and mitotic cell divisions, but not for S phase. Development 126:
2227-2239.

15 Brenner, S. (1974). The genetics of *Caenorhabditis elegans*. Genetics 77: 71-
94.

Browning, H., and Strome, S. (1996). A sperm-supplied factor required for
embryogenesis in *C. elegans*. Development 122: 391-404.

20 Bullock, T. L., Roberts, T. M., and Stewart, M. (1996). 2.5 Å resolution crystal
structure of the motile major sperm protein (MSP) of *Ascaris suum*. Journal of
Molecular Biology 263: 284-296.

C. elegans Sequencing Consortium. (1998). Genome sequence of the nematode
Caenorhabditis elegans: A platform for investigating biology. Science 282: 2012-
2018.

25 Cadigan, K. M., and Nusse, R. (1997). Wnt signaling: a common theme in
animal development. Genes and Development 11: 3286-3305.

Chase, D., Serafinas, C., Ashcroft, N., Kosinski, M., Longo, D., Ferris, D. K., and Golden, A. (2000). The polo-like kinase PLK-1 is required for nuclear envelope breakdown and the completion of meiosis in *Caenorhabditis elegans*. *Genesis: The Journal of Genetics and Development* 26: 26-41.

5 Chen, P. J., Singal, A., Kimble, J., and Ellis, R. E. (2000). A novel member of the Tob family of proteins controls sexual fate in *Caenorhabditis elegans* germ cells. *Developmental Biology* 217: 77-90.

10 Church, D. L., Guan, K.-L., and Lambie, E.J. (1995). Three genes of the MAP kinase cascade, *mek-2*, *mpk-1/sur-1* and *let-60 ras*, are required for meiotic cell cycle progression in *Caenorhabditis elegans*. *Development* 121: 2525-2535.

Clandinin, T. R., DeModena, J. A., and Sternberg, P. W. (1998). Inositol triphosphate mediates a RAS-independent response to LET-23 receptor tyrosine kinase activation in *C. elegans*. *Cell* 92: 523-533.

15 Colledge, W. H., Carlton, M. B. L., Udy, G. B., and Evans, M. J. (1994). Disruption of *c-mos* causes parthenogenetic development of unfertilized mouse eggs. *Nature* 370: 65-68.

20 Cordero, M. M., Cornish, T. J., Cotter, R. J., and Lys, I. A. (1995). Sequencing peptides without scanning the reflectron: post-source decay with a curved-field reflectron time-of-flight mass spectrometer. *Rapid Communications in Mass Spectrometry* 9: 1356-1361.

Coulson, A., Huynh, C., Kozono, Y., and Shownkeen, R. (1995). The physical map of the *Caenorhabditis elegans* genome. In: Epstein, H. F., and Shakes, D. C., editors. *Methods in Cell Biology. Caenorhabditis elegans: Modern Biological Analysis of an Organism*. San Diego: Academic Press. p. 533-550.

Cross, D. A., and Smythe, C. (1998). PD98059 prevents establishment of the spindle assembly checkpoint and inhibits the G2-M transition in meiotic but not mitotic cell cycles in *Xenopus*. *Experimental Cell Research* 241: 12–22.

Davis, S., Aldrich, T. H., Valenzuela, D. M., Wong, V. V., Furth, M. E.,
5 Squinto, S. P., and Yancopoulos, G. D. (1991). The receptor for ciliary neurotrophic factor. *Science* 253: 59-63.

Dernburg, A. F., McDonald, K., Moulder, G., Barstead, R., Dresser, M., and Villeneuve, A. M. (1998). Meiotic recombination in *C. elegans* initiates by a conserved mechanism and is dispensable for homologous chromosome synapsis. *Cell*
10 94: 387-398.

Ellis, R. E., and Kimble, J. (1995). The *fog-3* gene and regulation of cell fate in the germ line of *Caenorhabditis elegans*. *Genetics* 139: 561-577.

Ferby, I., Blazquez, M., Palmer, A., Eritja, R., and Nebreda, A. R. (1999). A novel p34(cdc2)-binding and activating protein that is necessary and sufficient to
15 trigger G(2)/M progression in *Xenopus* oocytes. *Genes and Development* 13: 2177-2189.

Ferrell, J. E., Jr. (1999). *Xenopus* oocyte maturation: new lessons from a good egg. *BioEssays* 21: 833-842.

Ferrell, J. E., Jr., Wu, M., Gerhart, J. C., and Martin, G. S. (1991). Cell cycle
20 tyrosine phosphorylation of p34cdc2 and a microtubule-associated protein kinase homolog in *Xenopus* oocytes and eggs. *Molecular and Cellular Biology* 11: 1965–1971.

Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E, and Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in
25 *Caenorhabditis elegans*. *Nature* 391: 806-811.

Fisher, D. L., Brassac, T., Galas, S., and Doree, M. (1999). Dissociation of MAP kinase activation and MPF activation in hormone-stimulated maturation of *Xenopus* oocytes. *Development* 126: 4537-4546.

Francis, R., Barton, M. K., Kimble, J., and Schedl, T. (1995). *gld-1*, a tumor
5 suppressor gene required for oocyte development in *Caenorhabditis elegans*.
Genetics 139: 579-606.

Gavrillets, G., *Nature* 403, 886 (2000).

Godeau, J. F., Schorderet-Slatkine, S., Hubert, P., and Baulieu, E. E. (1978).
Induction of maturation in *Xenopus laevis* oocytes by a steroid linked to a polymer.
10 *Proceedings of the National Academy of Sciences USA* 75: 2353-2357.

Gotoh, Y., Masuyama, N., Dell, K., Shirakabe, K., and Nishida, E. (1995).
Initiation of *Xenopus* oocyte maturation by activation of the mitogen-activated
protein kinase cascade. *Journal of Biological Chemistry* 270: 25898-25904.

Gotoh, Y., Moriyama, K., Matsuda, S., Okumura, E., Kishimoto, T.,
15 Kawasaki, H., Suzuki, K., Yahara, I., Sakai, H., and Nishida, E. (1991). *Xenopus* M
phase MAP kinase: isolation of its cDNA and activation by MPF. *EMBO Journal* 10
:2661-2668.

Grant, B., and Hirsh, D. (1999). Receptor-mediated endocytosis in the
Caenorhabditis elegans oocyte. *Molecular Biology of the Cell* 10: 4311-4326.

20 Greenstein, D., Hird, S., Plasterk, R. H. A., Andachi, Y., Kohara, Y., Wang,
B., Finney, M., and Ruvkun, G. (1994). Targeted mutations in the *Caenorhabditis*
elegans POU homeo box gene *ceh-18* cause defects in oocyte cell cycle arrest, gonad
migration, and epidermal differentiation. *Genes and Development* 8: 1935-1948.

Greenstein, D., unpublished results.

Gross, S. D., Schwab, M. S., Taieb, F. E., Lewellyn, A. L., Qian, Y. W., and Maller, J. L. (2000). The critical role of the MAP kinase pathway in meiosis II in *Xenopus oocytes* is mediated by p90(Rsk). *Current Biology* 10: 430-438.

Haaf, A., Butler, P. J., Kent, H. M., Fearnley, I. M., Roberts, T. M., Neuhaus, D., and Stewart, M. (1996). The motile major sperm protein (MSP) from *Ascaris suum* is a symmetric dimer in solution. *Journal of Molecular Biology* 260: 251-260.

Haccard, O., Lewellyn, A., Hartley, R. S., Erikson, E., and Maller, J. L. (1995). Induction of *Xenopus oocyte* meiotic maturation by MAP kinase. *Developmental Biology* 168: 677-682.

Hall, D. H., Winfrey, V. P., Blaeuer, G., Hoffman, L. H., Furuta, T., Rose, K. L., Hobert, O., and Greenstein, D. (1999). Ultrastructural features of the adult hermaphrodite gonad of *Caenorhabditis elegans*: relations between the germ line and soma. *Developmental Biology* 212: 101-123.

Hashimoto, N., Watanabe, N., Furuta, Y., Tamemoto, H., Sagata, N., Yokoyama, M., Okazaki, K., Nagayoshi, M., Takeda, N., Ikawa, Y., and Aizawa, S. (1994). Parthenogenetic activation of oocytes in *c-mos* deficient mice. *Nature* 370: 68-71.

Hill, D. P., Shakes, D. C., Ward, S., and Strome, S. (1989). A sperm-supplied product essential for initiation of normal embryogenesis in *Caenorhabditis elegans* is encoded by the paternal-effect embryonic-lethal gene, *spe-11*. *Developmental Biology* 136: 154-166.

Hill, K. L. and L'Hernault, S. W., submitted.

Hirsh, D., Oppenheim, D., and Klass, M. (1976). Development of the reproductive system of *Caenorhabditis elegans*. *Developmental Biology* 49: 200-219.

Holst, P. A., and Phemister, R. D. (1971). The prenatal development of the dog: Preimplantation events. *Biology of Reproduction* 5: 194-206.

Hooper, N. M., and Bashir, A. (1991). Glycosyl-phosphatidylinositol-anchored membrane proteins can be distinguished from transmembrane polypeptide-anchored proteins by differential solubilization and temperature-induced phase separation in Triton X-114. *Biochemical Journal* 280: 745-751.

5 Huang, W., Kessler, D. S., and Erikson, R. L. (1995). Biochemical and biological analysis of Mek1 phosphorylation site mutants. *Molecular Biology of the Cell* 6: 237-245.

Hubbard, E. J. A., and Greenstein, D. (2000). The *C. elegans* gonad: a test tube for cell and developmental biology. *Developmental Dynamics* 218: 2-22.

10 Hyttel, P., Farstad, W., Mondain-Monval, M., Bakke Lajord, K., and Smith, A. J. (1990). Structural aspects of oocyte maturation in the blue fox (*Alopex lagopus*). *Anatomy and Embryology* 181, 325-331.

15 Ishikawa, K., Hanaoka, Y., Kondo, Y., and Imai, K. (1977). Primary action of steroid hormone at the surface of amphibian oocyte in the induction of germinal vesicle breakdown. *Molecular and Cellular Endocrinology* 9: 91-100.

Italiano, J. E., Jr., Roberts, T. M., Stewart, M., and Fontana, C. A. (1982). Reconstitution *in vitro* of the motile apparatus from the amoeboid sperm of *Ascaris* shows that filament assembly and bundling move membranes. *Cell* 84: 105-114.

20 Jansen, G., Hazendonk, E., Thijssen, K. L., and Plasterk, R. H. (1997). Reverse genetics by chemical mutagenesis in *Caenorhabditis elegans*. *Nature Genetics* 17: 119-121.

25 Kagiwada, S., Hosaka, K., Murata, M., Nikawa, J., and Takatsuki, A. (1998). The *Saccharomyces cerevisiae* SCS2 gene product, a homolog of a synaptobrevin-associated protein, is an integral membrane protein of the endoplasmic reticulum and is required for inositol metabolism. *Journal of Bacteriology* 180: 1700-1708.

Kanatani, H., Shirai, H., Nakanishi, K., and Kurokawa, T. (1969). Isolation and identification of a meiosis inducing substance in starfish *Asterias amurensis*. *Nature* 221: 273-274.

5 Kaufmann, R., Spengler, B., and Lutzenkirchen, F. (1993). Mass spectrometric sequencing of linear peptides by product-ion analysis in a reflectron time-of-flight mass spectrometer using matrix-assisted laser desorption ionization. *Rapid Communications in Mass Spectrometry* 7: 902-910.

10 Kimble, J., and Hirsh, D. (1979). The postembryonic cell lineages of the hermaphrodite and male gonads in *Caenorhabditis elegans*. *Developmental Biology* 70: 396-417.

Kirby, C., Kusch, M., and Kemphues, K. (1990). Mutations in the *par* genes of *Caenorhabditis elegans* affect cytoplasmic reorganization during the first cell cycle. *Developmental Biology* 142: 203-215.

15 Klass, M. R., and Hirsh, D. (1981). Sperm isolation and biochemical analysis of the major sperm protein from *C. elegans*. *Developmental Biology* 84: 299-312.

Kosako, H., Gotoh, Y., and Nishida, E. (1994). Requirement for the MAP kinase kinase/MAP kinase cascade in *Xenopus* oocyte maturation. *EMBO Journal* 3: 2131-2138.

20 LaMunyon, C. W., and Ward, S. (1994). Assessing the viability of mutant and manipulated sperm by artificial insemination of *Caenorhabditis elegans*. *Genetics* 138: 689-692.

Laurent, F., Labesse, G., and de Wit, P. (2000). Molecular cloning and partial characterization of a plant VAP33 homologue with a major sperm protein domain. *Biochemical and Biophysical Research Communications* 270: 286-292.

25 Lee, M.-H. and Schedl, T., unpublished results.

Lewis, J. A., and Flemming, J. T. (1995). Basic culture methods. In: Epstein, H. F., and Shakes, D. C., editors. *Methods in Cell Biology. Caenorhabditis elegans: Modern Biological Analysis of an Organism*. San Diego: Academic Press. p. 3-29.

5 L'Hernault, S. W. (1997). Spermatogenesis. In: Riddle, D. L., Blumenthal, T., Meyer, B. J., and Priess, J. R., editors. *C. elegans II*. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press. p. 271-294.

10 L'Hernault, S. W., and Roberts, T. M. (1995). Cell biology of nematode sperm. In: Epstein, H. F., and Shakes, D. C., editors. *Methods in Cell Biology. Caenorhabditis elegans: Modern Biological Analysis of an Organism*. San Diego: Academic Press. p. 273-301.

L'Hernault, S. W., Arduengo, P. M., *J. Cell Biol.* **119**, 55 (1992).

Lin, R.J., Kao, H. Y., Ordentlich, P., and Evans, R. M. (1998). The transcriptional basis of steroid physiology. *Cold Spring Harbor Symposium on Quantitative Biology* 63: 577-585.

15 Liu, X., Kim, C. N., Yang, J., Ronald Jemmerson, R., and Wang, X. (1996). Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. *Cell* 86: 147-157.

20 MacMorris, M., Spieth, J., Madej, C., Lea, K., and Blumenthal, T. (1994). Analysis of the VPE sequences in the *Caenorhabditis elegans vit-2* promoter with extrachromosomal tandem array-containing transgenic strains. *Molecular and Cellular Biology* 14: 484-491.

Masui, Y., and Clarke, H. J. (1979). Oocyte maturation. *International Review of Cytology* 57: 185-282.

25 Masui, Y., and Markert, C. L. (1971). Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes. *Journal of Experimental Zoology* 177: 129-145.

McCarter, J., Bartlett, B., Dang, T., and Schedl, T. (1997). Soma-germ cell interactions in *Caenorhabditis elegans*: Multiple events in germline development require the somatic sheath and spermathecal lineages. *Developmental Biology* 181: 121-143.

5 McCarter, J., Bartlett, B., Dang, T., and Schedl, T. (1999). On the control of oocyte meiotic maturation and ovulation in *C. elegans*. *Developmental Biology* 205: 111-128.

10 Mendez, R., Hake, L. E., Andresson, T., Littlepage, L. E., Ruderman, J. V., and Richter, J. D. (2000). Phosphorylation of CPE binding factor by Eg2 regulates translation of *c-mos* mRNA. *Nature* 404: 302-307.

15 Miller, M. A., Nguyen V. Q., Lee, M., Kosinski, M., Schedl, M., Caprioli, R. M., and Greenstein D. (2001) A Sperm Cytoskeletal Protein That Signals Oocyte Meiotic Maturation and Ovulation. *Science* 2001 291: 2144-2147.

20 Morgan, D. O. (1997). Cyclin-dependent kinases: engines, clocks, and microprocessors. *Annual Review of Cell and Developmental Biology* 13: 261-291.

25 Muhlrads, D., Hunter, R., and Parker, R. (1992). A rapid method for localized mutagenesis of yeast genes. *Yeast* 8: 79-82.

 Mukherjee, S., Ghosh, R. N., and Maxfield, F. R. (1997). Endocytosis. *Physiology Reviews* 77: 759-803.

 Munson, P. J., and Rodbard, D. (1980). Ligand: a versatile computerized approach for characterization of ligand-binding systems. *Analytical Biochemistry* 107: 220-239.

 Myers, C. D., Goh, P.-Y., Allen, T. St. C., Bucher, E. A., and Bogaert, T. (1996). Developmental genetic analysis of Troponin T mutations in striated and nonstriated muscle cells of *Caenorhabditis elegans*. *Journal of Cell Biology* 132: 1061-1077.

Nance, J., Minniti, A. N., Sadler, C., and Ward, S. (1999). *spe-12* encodes a sperm cell surface protein that promotes spermiogenesis in *Caenorhabditis elegans*. Genetics 152: 209-220.

5 Nelson, G. A., Roberts, T. M., and Ward, S. (1982). *C. elegans* spermatozoan locomotion: Amoeboid movement with almost no actin. Journal of Cell Biology 92: 121-131.

Nelson, G. A., and Ward, S. (1980). Vesicle fusion, pseudopod extension and amoeboid motility are induced in nematode spermatids by the ionophore monensin. Cell 19: 457-464.

10 Palmer, A. and Nebreda, A. R., *Prog. Cell Cycle Res.* 4, 131 (2000).

Pandey, A., and Mann, M. (2000). Proteomics to study genes and genomes. Nature 405: 837-846.

15 Pavalko, F. M., and Roberts, T. M. (1989). Posttranslational insertion of a membrane protein on *Caenorhabditis elegans* sperm occurs without de novo protein synthesis. Journal of Cellular Biochemistry 41: 57-70.

Podbilewicz, B. (1996). ADM-1, a protein with metalloprotease- and disintegrin-like domains, is expressed in syncytial organs, sperm, and sheath cells of sensory organs in *Caenorhabditis elegans*. Molecular Biology of the Cell 7: 1877-1893.

20 Posada, J., and Cooper, J. A. (1992). Requirements for phosphorylation of MAP kinase during meiosis in *Xenopus* oocytes. Science 255: 212-215.

Qian, Y. W., Erikson, E., and Maller, J. L. (1999). Mitotic effects of a constitutively active mutant of the *Xenopus* polo-like kinase Plx1. Molecular and Cellular Biology 19: 8625-8632.

25 Ramalho-Santos, J., *et al.*, *Dev. Biol.* 223, 54 (2000).

Resing, K. A., Mansour, S. J., Hermann, A. S., Johnson, R. S., Candia, J. M., Fukasawa, K., Vande Woude, G. F., and Ahn, N. G. (1995). Determination of v-Mos-catalyzed phosphorylation sites and autophosphorylation sites on MAP kinase kinase by ESI/MS. *Biochemistry* 34: 2610–2620.

5 Roberts, T. M. (1983). Crawling *C. elegans* spermatozoa contact the substrate only by their pseudopods and contain 2-nm filaments. *Cell Motility* 3: 333-347.

Roberts, T. M., Pavalko, F. M., and Ward, S. (1986). Membrane and cytoplasmic proteins are transported in the same organelle complex during nematode spermatogenesis. *Journal of Cell Biology* 102: 1787-1796.

10 Roberts, T. M., and Stewart, M. (1995). Nematode sperm locomotion. *Current Opinion in Cell Biology* 7: 13-17.

Roberts, T. M., and Stewart, M. (2000). Acting like actin. The dynamics of the nematode major sperm protein (msp) cytoskeleton indicate a push-pull mechanism for amoeboid cell motility. *Journal of Cell Biology* 149: 7-12.

15 Roberts, T. M., and Ward, S. (1982a). Membrane flow during nematode spermiogenesis. *Journal of Cell Biology* 92: 113-120.

Roberts, T. M., and Ward, S. (1982b). Centripetal flow of pseudopodial surface components could propel the amoeboid movement of *C. elegans* spermatozoa. *Journal of Cell Biology* 92: 132-138.

20 Rose, K. L., Winfrey, V. P., Hoffman, L. H., Hall, D. H., Furuta, T., and Greenstein D. (1997). The POU gene *ceh-18* promotes gonadal sheath cell differentiation and function required for meiotic maturation and ovulation in *Caenorhabditis elegans*. *Developmental Biology* 192: 59-77.

25 Rutledge, E., Bianchi, L., Christensen, M., Morrison, R., Broslat, A., Beld, A., George Jr., A. L., Greenstein, D., and Strange, K. (2000). CLH-3: a *C. elegans* ClC-2

chloride channel orthologue regulated by cell cycle events and involved in soma-
germline intercellular signaling. Submitted.

Sagata, N. (1997). What does Mos do in oocytes and somatic cells?
BioEssays19: 13-21.

5 Sagata, N., Oskarsson, M., Copeland, T., Brumbaugh, J., and Vande Woude,
G. F. (1988). Function of *c-mos* proto-oncogene product in meiotic maturation in
Xenopus oocytes. Nature 335:519-525.

10 Sagata, N., Watanabe, N., Vande Woude, G. F., and Ikawa, Y. (1989). The *c-
mos* proto-oncogene product is a cytostatic factor responsible for meiotic arrest in
vertebrate eggs. Nature 342: 512-518.

Schagger, H., and von Jagow, G. (1987). Tricine-sodium dodecyl sulfate-
polyacrylamide gel electrophoresis for the separation of proteins in the range from 1
to 100 kDa. Analytical Biochemistry 166: 368-379.

15 Schedl, T., and Kimble, J. (1988). *fog-2*, a germ-line-specific sex
determination gene required for hermaphrodite spermatogenesis in *C. elegans*.
Genetics 119: 43-61.

Schulz, J. R., *et al.*, *J. Biol. Chem.* **273**, 24355 (1998).

20 Seed, B., and Aruffo, A. (1987). Molecular cloning of the CD2 antigen, the T-
cell erythrocyte receptor, by a rapid immunoselection procedure. Proceedings of the
National Academy of Sciences U S A 84: 3365-3369.

Shakes, D. C., and Ward, S. (1989). Initiation of spermiogenesis in *C. elegans*:
A pharmacological and genetic analysis. Developmental Biology 134: 189-200.

Sheets, M. D., Wu, M., and Wickens, M. (1995). Polyadenylation of *c-mos*
mRNA as a control point in *Xenopus* meiotic maturation. Nature 374: 511-516.

25 Skehel, P. A., Armitage, B. A., Bartsch, D., Hu, Y., Kaang, B. K., Siegelbaum,
S. A., Kandel, E. R., and Martin, K. C. (1995). Proteins functioning in synaptic

transmission at the sensory to motor synapse of *Aplysia*. *Neuropharmacology* 34: 1379-1385.

Skehel, P. A. *et al.*, *Science* **269**, 1580 (1995).

Smith, H. E., and Ward, S. (1998). Identification of protein-protein
5 interactions of the major sperm protein (MSP) of *Caenorhabditis elegans*. *Journal of Molecular Biology* 279: 605-619.

Smith, L. D., and Ecker, R. E. (1969). Role of the oocyte nucleus in physiological maturation in *Rana pipiens*. *Developmental Biology* 19: 281-309.

Smith, L. D., and Ecker, R. E. (1971). The interaction of steroids with *Rana*
10 *pipiens* oocytes in the induction of maturation. *Developmental Biology* 25: 232-247.

Soussan, L. *et al.*, *J. Cell Biol.* **146**, 301 (1999).

Spector, D. L., Goldman, R. D., and Leinwand, L. A. (1998). Plasma
membrane isolation using the cationic colloidal silica isolation technique. In *Culture and Biochemical Analysis of Cells*. K. Janssen, editor. p. 35.1-35.14. Cold Spring
15 Harbor Laboratory Press: Plainview, NY.

Starck, J., Gibert, M.-A., Brun, J., and Bosch C. (1983), Ribosomal RNA
synthesis and processing during oogenesis of the free living nematode *C. elegans*.
Comparative Biochemistry and Physiology 75B: 575-580.

Stebbins-Boaz, B., Hake, L. E., and Richter, J. D. (1996). CPEB controls the
20 cytoplasmic polyadenylation of cyclin, Cdk2 and *c-mos* mRNAs and is necessary for
oocyte maturation in *Xenopus*. *EMBO Journal* 5: 2582-2592.

Strome, S. (1986). Fluorescence visualization of the distribution of
microfilaments in gonads and early embryos of the nematode *C. elegans*. *Journal of Cell Biology* 103: 2241-2252.

Sulston, J., and Hodgkin, J. (1988). Methods. In *The Nematode Caenorhabditis elegans*. W. B. Wood, editor, p. 587-606. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Swofford, D., "PAUP: Phylogenetic analysis using parsimony." Illinois
5 National History Survey, Champaign (1993).

Vacquier, V. D., *Science* **281**, 1995 (1998).

Veenstra, J. A. (2000). Mono- and dibasic proteolytic cleavage sites in insect neuroendocrine peptide precursors. *Archives of Insect Biochemistry and Physiology* 43: 49-63.

10 Ward, S. (1986). Asymmetric localization of gene products during the development of *C. elegans* spermatozoa. In *Gametogenesis and the Early Embryo*. 44th Symposium of the Society for Developmental Biology. Gall, J. G., (ed). p.55-75. Alan R. Liss, NY.

15 Ward, S., Argon, Y., and Nelson, G. A. (1981). Sperm morphogenesis in wild-type and fertilization-defective mutants of *C. elegans*. *Journal of Cell Biology* 91: 26-44.

20 Ward, S., Burke, D. J., Sulston, J. E., Coulson, A. R., Albertson, D. G., Ammons, D., Klass, M., and Hogan, E. (1988). Genomic organization of major sperm protein genes and pseudogenes in the nematode *Caenorhabditis elegans*. *Journal of Molecular Biology* 199, 1-13.

Ward, S., and Carrel, J. S. (1979). Fertilization and sperm competition in the nematode *Caenorhabditis elegans*. *Developmental Biology* 73: 304-321.

Ward, S., Hogan, E., and Nelson, G. A. (1983). The initiation of spermiogenesis in the nematode *C. elegans*. *Developmental Biology* 98: 70-79.

25 Ward, S., and Klass, M. (1982). The location of the major protein in *C. elegans* sperm and spermatocytes. *Developmental Biology* 92: 203-208.

Ward, S., and Miwa, J. (1978). Characterization of temperature-sensitive, fertilization-defective mutants of the nematode *C. elegans*. *Genetics* 88: 285-303.

Ward, S., Roberts, T. M., Strome, S., Pavalko, F. M., and Hogan, E. (1986). Monoclonal antibodies that recognize a polypeptide antigenic determinant shared by multiple *C. elegans* sperm-specific proteins. *Journal of Cell Biology* 102: 1778-1786.

Wimalawansa, S. J. (1995). Purification and biochemical characterization of Neuropeptide Y₂ receptor. *The Journal of Biological Chemistry* 270: 18523-18530.

Wolf, N., Hirsh, D., and McIntosh, J. R. (1978). Spermatogenesis in males of the free-living nematode, *C. elegans*. *Journal of Ultrastructure Research* 63: 155-169.

Yasunaga, S., Grati, M., Cohen-Salmon, M., El-Amraoui, A., Mustapha, M., Salem, N., El-Zir, E., Loiselet, J., and Petit, C. (1999). A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness. *Nature Genetics* 21:363-369.

Yew, N., Mellini, M. L., and Vande Woude, G. F. (1992). Meiotic initiation by the mos protein in *Xenopus*. *Nature* 355: 649-652.

Yung, Y., *et al.*, *FEBS Lett.* **408**, 292 (1997).

4. To prepare SCM, purified sperm (26) were incubated in M9 buffer (~5 x 10⁷ sperm/ml) for 1-16 hrs at 20°C. Sperm were removed by centrifugation for 5 min at 14,000 rpm in an Eppendorf microcentrifuge (model 5415C) and filtration through a 0.22 µm cellulose acetate filter (Costar). Samples (~50 pl) were microinjected into the uterus of *fog-2(q71)* (3) adult females (30 hrs post-L4 at 20°C). Following injection, females were anesthetized for 20 minutes with 0.1% tricaine/0.01% tetramisole (32) in M9. Oocyte maturation and sheath cell contraction rates were monitored by time-lapse video microscopy (1) for 70 minutes.

5. SCM or sperm lysates (by vortexing with glass beads) were fractionated on C₄ and C₁₈ columns (Vydac) using an acetonitrile gradient (0-100%) mobile phase. TFA (0.1%) was added to the mobile phase to sharpen peaks by ion pairing. Absorbance peaks (214 nm) were collected manually, dialyzed against M9, and
5 bioassayed. Active fractions were analyzed by MALDI-TOF mass spectrometry using internal molecular weight standards (insulin, cytochrome C and myoglobin).

6. Post source decay mass spectrometry (33) of a 1960 Da peptide, generated by tryptic digestion of the active fraction, yielded the sequence IVFNAPYDDKHTYHIK, which matched MSP.

10 9. His-tagged MSP-77, MSP-38, and MSP(1-106) were expressed in *Escherichia coli* M15[pRep4] (Qiagen) and purified under native conditions by Ni-NTA affinity chromatography (>99% pure by SDS-PAGE and mass spectrometry). The extinction coefficient ϵ (275 nm) of MSP was estimated by amino acid analysis of a purified His-tagged MSP-77 standard. MSP concentrations were determined by
15 amino acid hydrolysis, SDS-PAGE, and spectrophotometrically using ϵ (275 nm) = $3.29 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$.

20 10. Anti-MSP (26) or control EMB-30 antibodies (34) were injected (~40 $\mu\text{g/ml}$) into adult wild-type N2 hermaphrodites (24 hr post-L4 at 20°C). The injected animals were cultured individually with food for a 3 hr time period and total ovulations were determined. The effect of antibody injection on oocyte maturation was determined by time lapse video microscopy. A two-sample t-test was used to compare results of MSP injections with controls.

12. The C-terminal MSP peptide (EWFQGDGMVRRKNLPIEYNP) was prepared by solid-phase synthesis and purified by HPLC (Research Genetics).

15. Diphosphorylated MAP kinase was detected in dissected and fixed (3% paraformaldehyde) gonadal preparations using indirect immunofluorescence with the antibody MAPK-YT (35) (Sigma). In *C. elegans* preparations, MAPK-YT only recognizes *mpk-1* map kinase gene products (36). Gonads were stained 8, 40, or 50 min post MSP injection. Activated MAP kinase was detected 40 and 50 min post-injection but was not detectable 8 min post injection.

22. Phylogenetic analyses were performed using maximum parsimony and neighbor-joining methods. Amino acid sequences from MSP and MSP-like domains of several representative VAPs were used in the analyses. For parsimony, the heuristic search option of PAUP* 3.1 (37) was used for tree construction, with 200 random order taxon addition replicates and tree bisection and reconnection branch swapping. Bacterial PapD, which is structurally related to MSP, was used as the outgroup. The "protpars" matrix of PAUP* 3.1 was used to weigh amino acid substitutions. To obtain bootstrap values, 100 bootstrap replicates were performed using simple taxon addition with tree bisection and reconnection branch swapping.

The present invention is not limited by mechanism or theory. Although there have been described general and specific embodiments of the invention herein, these embodiments do not limit the scope of the invention except as set forth in the Claims below.